medRxiv preprint doi: https://doi.org/10.1101/2023.03.22.23287570; this version posted March 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 1 Sterile faecal filtrate transplantation alters phage-microbe dynamics in
- 2 individuals with metabolic syndrome: a double blind, randomised, placebo-

3 controlled clinical trial assessing efficacy and safety

- 4
- 5 Koen Wortelboer^{1,2,3,7}, Patrick A. de Jonge^{1,2,3,7}, Torsten P.M. Scheithauer^{1,2,3}, Ilias
- 6 Attaye^{2,3,4}, E. Marleen Kemper^{1,5}, Max Nieuwdorp^{1,2,3,4,6}, Hilde Herrema^{1,2,3,*}
- 7
- 8 ¹: Amsterdam UMC location University of Amsterdam, Experimental Vascular Medicine,
- 9 Amsterdam, The Netherlands.
- 10 ²: Amsterdam Cardiovascular Sciences, Diabetes & Metabolism, Amsterdam, The
- 11 Netherlands.
- ³: Amsterdam Gastroenterology Endocrinology Metabolism, Endocrinology, metabolism and
- 13 nutrition, Amsterdam, The Netherlands.
- ⁴: Amsterdam UMC location University of Amsterdam, Vascular Medicine, Amsterdam, The
- 15 Netherlands.
- ⁵: Amsterdam UMC location University of Amsterdam, Department of Pharmacy and Clinical
- 17 Pharmacology, Amsterdam, The Netherlands.
- ⁶: Amsterdam UMC location Vrije University Medical Center, Department of Internal
- 19 Medicine, Diabetes Center, Amsterdam, The Netherlands.
- ⁷: These authors contributed equally.
- 21 *: Correspondence: Meibergreef 9, 1105AZ Amsterdam; h.j.herrema@amsterdamumc.nl
- 22

23 Keywords

- 24 bacteriophages; gastrointestinal microbiome; faecal microbiota transplantation; sterile faecal
- 25 filtrate transplantation; metabolic syndrome; faecal virome transplantation

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 ABSTRACT

27 Objective

Bacteriophages (phages) are viruses of bacteria and have been shown to shape microbial communities. Previous studies have shown that altering the microbiota through faecal microbiota transplantation (FMT) can improve insulin resistance in individuals with metabolic syndrome (MetSyn). Interestingly, similar effects were observed in diet-induced obese mice after a faecal virome transplantation (FVT), raising the question whether phages of a healthy donor can improve glucose metabolism in individuals with MetSyn as well.

34 Design

We performed a double-blind, randomised, placebo-controlled pilot study in which 24 individuals with MetSyn were randomised to receive a sterile faecal filtrate transplantation (FFT) from a lean healthy donor or a placebo. From baseline up to 28 days, we assessed safety, effects on glucose metabolism, and longitudinal changes within the bacteriome and phageome.

40 Results

41 The FFT was well-tolerated and safe and glucose variability (time between 3.9-10 mmol/L 42 glucose) improved in the week following the FFT. Glucose excursions during oral glucose 43 tolerance tests were comparable in both the FFT and placebo group after 28 days. The phage virion composition was significantly altered two days after FFT as compared to placebo. 44 Moreover, we found that FFT induced more virulent phage-microbe interactions within the first 45 two days after administration, while these interactions appeared more temperate in the 46 47 placebo group. 48 Conclusion We provide evidence that gut phages from a healthy donor can be safely administered to 49 50 transiently alter the gut microbiota of recipients, thereby providing a critical basis for follow-up

- 51 studies.
- 52 Trial registration number
- 53 Dutch Trial Registry: NL8289
- 54

55 **INTRODUCTION**

The metabolic syndrome (MetSyn) constitutes a major global health concern¹. This combination of clinical manifestations that are associated with insulin resistance affects nearly a quarter of the world population and increases the risk for cardiometabolic disease, such as type 2 diabetes (T2D) and cardiovascular disease^{2,3}. The intestinal microbiota are increasingly seen as contributors to these diseases, e.g., through production of certain microbial metabolites and induction of low-grade inflammation^{4,5}.

62

Previously reported microbial effects on human health have been mainly attributed to the 63 bacterial component of the microbiota⁶. However, the gut microbiome is an ecosystem, which, 64 in addition to bacteria, contains viruses, archaea, fungi, and protists⁷. The viral component 65 predominantly comprises bacteriophages (98%)⁸, which are present in similar numbers as 66 bacteria in the gut⁹. Bacteriophages (phages from hereon) are bacterial viruses that 67 exclusively infect bacteria and, by doing so, often either kill bacteria (lysis) or incorporate 68 themselves into the bacterial genome (lysogeny)¹⁰. Consequently, phages shape microbial 69 communities in many ecosystems^{11,12}. Moreover, phages have been implicated in human 70 (gastrointestinal) disease^{13–16}, including diabetes^{17,18}. We recently described decreased 71 72 richness and diversity of the gut phageome in MetSyn, together with a larger inter-individual 73 variation and altered composition¹⁹.

74

Considering their ability to modulate gut bacteria and their function²⁰, phages are of special 75 76 interest in ongoing endeavours to alter the human gut microbiome to benefit human health. 77 Furthermore, the emergence of multidrug-resistant bacteria has led to an increasing interest in phage therapy, in which host-specific phages target specific pathogenic bacteria without 78 affecting the commensal microbiota^{21,22}. Such phage cocktails can be very effective in treating 79 monoclonal bacterial infections, but are in general not sufficient to (beneficially) alter a 80 complete microbiome^{23,24}. Therefore, there is growing interest in the transfer of virus-like 81 82 particles (VLP) isolated from the faecal microbiota, generally called a faecal virome 83 transplantation (FVT). In mice, it has been shown that FVT induced a comparable effect as a faecal microbiota transplantation (FMT), in which the complete faecal microbiota of a healthy 84 donor is transferred^{25,26}. Moreover, in a small human pilot study, an FMT depleted of bacteria, 85 also known as a sterile faecal filtrate transplantation (FFT), was successful in curing five 86 individuals from a recurrent *Clostridioides difficile* infection²⁷. Compared to FMTs, an FFT or 87 88 FVT depleted of living microorganisms has a lower risk of transferring unknown pathogenic bacteria, which might improve safety. 89

Modulation of gut microbiota composition through FMT has been shown to improve peripheral insulin sensitivity in individuals with MetSyn^{28,29}. Moreover, an FVT from lean donor mice was able to decrease weight gain and normalize blood glucose tolerance in diet-induced obese mice³⁰. This effect was likely mediated through alterations in the gut microbiota induced by phages, as prior treatment with antibiotics disrupted the bacterial hosts and thereby counteracted the effect of the FVT. This raised the question whether transfer of faecal phages could induce a similar effect as FMT in human individuals with MetSyn.

98

In this double-blind, randomized, placebo-controlled pilot study, we provide proof of concept
that gut phages from lean healthy donors can be safely administered to MetSyn recipients.
Moreover, these phages have the potential to improve glycemic variability and alter phagemicrobe dynamics. Although follow up studies in well-matched donor-recipient pairs are
needed, this study provides a critical basis to do so.

104

105 **RESULTS**

106 Inclusion of subjects and donors

107 A total of 82 subjects signed the informed consent form and were screened from October 108 2019, of which 24 subjects were included and finished the study before December 2020 (figure 109 S1A). Most subjects were excluded because they did not have MetSyn according to the National Cholesterol Education Program (NCEP) criteria for the metabolic syndrome³¹. For the 110 faeces donors, 24 subjects signed informed consent and were stepwise screened, resulting 111 112 in 6 eligible donors (figure S1B). Potential donors failed screening mainly due to carriage of 113 parasites (11/24, 46%), followed by positive stool tests for pathogens (4/24, 17%) and exclusion based on questionnaire (3/24, 13%). Of these 6 eligible donors, only 3 (3/24, 13%) 114 115 donated faeces for the production of a sterile faecal filtrate. Therefore, an additional 2 donors 116 who were already actively donating for other FMT studies were included³².

117

The 24 included MetSyn subjects were randomly assigned to receive an FFT (n=12) or 118 119 placebo (n=12). As shown in table 1, both groups were similar in baseline characteristics, such as age, sex, body mass index (BMI), and other MetSyn-associated parameters. Only the 120 121 systolic blood pressure was significantly higher in the placebo group, although this difference 122 disappeared at baseline and follow-up visits and was therefore probably a case of white coat 123 hypertension during the screening. None of the individuals with MetSyn used concomitant 124 medication and their diets were similar (table S1). Compared to the healthy donors, the MetSyn subjects differed, as expected, in almost every aspect of MetSyn-associated 125 parameters (table 1). 126

128 FFT is safe and well-tolerated

129 The FFT was well-tolerated by the participants and there were no serious adverse events. Compared to the placebo group, subjects in the FFT group did report more adverse events 130 (AEs) that were likely or possibly related to the intervention (eight vs two AEs), although this 131 132 difference was not statistically significant (table 2). All adverse events that may have been related to the intervention were mild gastrointestinal complaints, such as diarrhoea, 133 constipation, bloating, and nausea. Looking at the clinical safety parameters for liver and renal 134 135 function, haematology, and inflammation, we did not observe any differences between the FFT and placebo groups (table 2). Interestingly, in both groups there was a significant increase 136 in urea levels, which could be explained by the laxative that was used the evening prior to day 137 0, leading to less degradation of amino acids through the liver at baseline, and therefore less 138 139 urea.

140

141 FFT improved glucose variability

Prior to the intervention and after 28 days at follow-up, subjects underwent an oral glucose 142 143 tolerance test (OGTT) to assess their glucose metabolism (figure 1A). Glucose and C-peptide 144 excursions during the OGTT at day 28 after the intervention were similar in the FFT and 145 placebo group (figure 1B-D), as were within group alterations (day 0 vs day 28). In addition, we observed similar fasting glucose and insulin levels, insulin resistance (HOMA-IR) (figure 146 1E), and HbA1c values between the FFT and placebo group at day 28 (table 3). Interestingly, 147 we did observe a significant increase in fasted insulin levels and associated HOMA-IR values 148 149 between day 0 and 28 within both the FFT and placebo group. However, when comparing 150 these two measures between the screening visit and day 28, they were similar. We can only speculate that this drop in insulin levels and associated HOMA-IR value at the baseline visit 151 152 resulted from the laxative use the day prior to the intervention. Other baseline characteristics 153 remained stable after intervention and were similar between the FFT and placebo group, such as BMI, blood pressure and cholesterol (table 3). 154

155

In addition to the OGGT, subjects wore a continuous glucose monitoring (CGM) device (Freestyle Libre) from one week prior till one week after intervention. Looking at the results from the CGM measurements, the FFT and placebo group showed overall similar glucose levels and glucose variability markers after intervention (table S2). However, within the FFT group we identified a nominal significant improvement in the time between 3.9-10 mmol/L glucose after intervention (from 95.5% to 97.5%, p-value = 0.02)(figure 1F). This indicated an improvement in glucose variability within the FFT group in the week after intervention.

163

165 Bacterial and viral diversity remain stable after FFT

To assess the effect of the FFT on the bacteriome and phageome, we collected multiple faecal samples from baseline up to day 28, and performed whole genome shotgun (WGS) sequencing (figure 2A)³³. The phage populations derived from this WGS fraction mainly consist of integrated prophages. To study phage virions, VLPs were isolated from the same faecal samples, lysed, and the purified DNA was shotgun sequenced as previously described¹⁹. After combining all viral sequences from WGS and VLP fractions, we clustered them at 95% similarity into viral populations (VPs), a level comparable to species in bacteria³⁴.

173

Analysis of beta diversity showed that both the VLP and WGS phageomes were 174 indistinguishable between donor and MetSyn participants at baseline (VLP (figure S2A), 175 PERMANOVA p = 0.725; WGS (figure S2B), PERMANOVA p = 0.672). While this defies our 176 earlier findings¹⁹, this is likely due to the highly individual-specific viromes and the relatively 177 small size of our study. Notably, the VLP phageome was radically different from the WGS 178 phageome (figure S2C, PERMANOVA p = 0.001). This is one of the first studies to directly 179 180 compare the VLP and WGS phageomes within the same patient longitudinally, as previous 181 studies used different cohorts to compare the VLP and WGS phageomes⁸.

182

183 Next, we looked at the effect of FFT on the bacterial and viral richness (figure 2B) and alpha diversity in MetSyn subjects (figure 2C). These were comparable throughout the study 184 between the FFT and placebo intervention. Interestingly, in both groups the bacterial richness 185 186 and α -diversity reduced slightly the first days after the intervention, which was resolved by day 187 14 to 28. A similar trend was observed for the richness and diversity of the WGS phageome, which consists mainly of prophages that could have been depleted with their bacterial hosts. 188 In contrast, the richness of the VLP phageome increased slightly by day 2 in both groups, 189 while the α -diversity decreased only in the placebo group, albeit non-significant (p = 0.2). 190

191

192 Increase in new phages independent of the intervention

To determine whether phages from the donors transferred to the recipients, we looked at the 193 abundance of phages shared between donor and recipient. Although not significant, after FFT 194 195 the VPs shared with the donor within the WGS phageome increased up to day 14 (figure 3A). 196 For the VLP phageome we found an opposite effect, where the VPs shared with the donor 197 decreased non-significantly after the FFT (figure 3B). The broader effect of the FFT on the 198 phageomes was determined by analysing the abundance of new phages that appeared after the FFT within the WGS phageome (figure 3C) and within the VLP phageome (figure 3D). In 199 200 both groups the abundance of new phages increased over time and although not significant, 201 this increase was slightly higher in the FFT group, especially in the VLP phageome on day 2

(p = 0.2). These results seem to indicate that the phageomes were perturbed in both the placebo and FFT groups. It further shows that donor-derived phages, especially the VLPs, were either mostly immediately removed from the gut or their engraftment was balanced with the removal of pre-existing VPs shared with the donors.

206

207 FFT alters the phage composition of the VLP fraction

208 Subsequently, we looked at compositional changes within the bacteriome, WGS phageome, 209 and VLP phageome (figure 4A). Principal response curves showed no overall effect of the FFT 210 on any of these communities compared to placebo, except for a significantly different composition of the VLP phageome on day 2 (p=0.02). This difference in composition within 211 the VLP phageome on day 2 was also evident from a separate principal component analysis 212 213 (figure 4B, PERMANOVA p=0.028). As this pointed toward a short-term effect of the FFT, we looked more specifically into VLP communities on day 2 and found 216 VPs that were 214 differentially abundant between the FFT and placebo groups (figure 4C and table S3). 215

216

217 To get a better understanding of these phages, we looked at the bacterial host species that 218 these differentially abundant VPs can infect. We observed 10 bacterial hosts of which the 219 phages were significantly enriched among these VPs (figure 4D). The phages infecting some 220 of these host bacteria, like Roseburia intestinalis and Bacteroides cellulosilyticus, were present in both FFT and placebo treatment groups. But others, like Sutterella wadsworthensis 221 and Scatocola faecigallinarum, were notably exclusively differentially abundant in one of the 222 223 two treatment groups. The only host species enriched among differentially abundant VPs and 224 more prevalent in the placebo group was S. wadsworthensis, a betaproteobacterium associated with gastrointestinal infections. Those more prevalent among the FFT group were 225 226 taxonomically diverse, belonging to the Bacteroidetes (Bacteroides fragilis and B. 227 cellulosilyticus), Firmicutes (R. intestinalis, Faecousia, Eisenbergiella, CAG-882 and CAG-170) and Proteobacteria (S. faecigallinarum and CAG-267). 228

229

230 **FFT induces an antagonistic phage-microbe interaction**

Intrigued by the presence of differentially abundant VPs two days after FFT, we determined 231 232 whether the dynamics between phages and their microbial hosts had changed. For this, we 233 linked VPs to metagenome assembled genomes (MAGs) from our WGS sequencing dataset 234 and calculated the mean abundance change for all VP-MAG pairs belonging to a given species 235 in a given sample. This showed opposing relationships between MAG and VP abundance in the first two days of the intervention (figure 5A): this was negatively correlated for the FFT 236 group (R = -0.13, p = 0.005) and positively correlated in the placebo group (R = 0.17, p 237 238 <0.001). These results indicated that the FFT group was dominated by virulent phage-

bacterium interactions, while they were more likely to be temperate or chronic in the placebo group. These effects intriguingly were less pronounced when comparing days 2 and 28 (FFT: R = -0.043, p = 0.24; placebo: R = 0.12, p = 0.004; figure 5B), and completely absent when comparing days 0 and 28 (figure 5C). Thus, the overall effect of the FTT on phage-host interactions seemed pronounced but short-lived.

244

245 **DISCUSSION**

246 This is the first randomized controlled clinical trial in which a sterile faecal filtrate was administered to human individuals. In the present study, the FFT was well-tolerated and safe, 247 with recipients experiencing solely mild gastrointestinal adverse effects. As the study group is 248 small, larger studies with a longer follow-up are warranted to fully assess the safety profile of 249 the FFT. However, compared to FMTs, an FFT depleted of living microorganisms has a lower 250 risk of transferring unknown pathogenic bacteria²⁷. Since FMT has a good safety profile^{35,36}, 251 this most likely holds true for FFTs as well. Compared to FMTs, it is relatively easier to further 252 optimise and standardise FFTs, e.g., through lyophilization and encapsulation of faecal filtrate, 253 254 as the viability of the many strict anaerobic bacteria does not have to be preserved. Such 255 developments of FFT will ease the administration, reduce the invasiveness, and provide an 256 option for prolonged or maintenance therapy, even in a home-setting.

257

While we did find a slight improvement of the glucose variability in the FFT group, expressed 258 as the time between 3.9-10 mmol/L glucose, the FFT and placebo groups showed similar 259 260 glucose excursions during the OGGT performed at day 28. Previously, an FVT in diet-induced obese mice reduced weight gain and improved blood glucose tolerance³⁰. However, FVTs 261 differ slightly from FFTs, with phages being more concentrated and washed to reduce bacterial 262 debris, metabolites and antimicrobial peptides. Moreover, in this previous study, several donor 263 264 phageomes were combined, resulting in a highly diverse phageome. In addition, compared to humans, microbiomes of mice are more similar due to the same housing and diet³⁷, thereby 265 increasing the chance of highly specific bacteriophages encountering their host and, 266 subsequently, modulating the microbiota. In humans, improvement of insulin sensitivity after 267 lean healthy donor FMT in individuals with MetSyn has been reported^{28,29}. These studies had 268 269 a comparable study design as present study, with the major difference being the absence of 270 the faecal bacteria in the intervention. Although this is not a direct comparison, we speculate 271 that, in the case of MetSyn, the beneficial bacteria transplanted during an FMT significantly 272 contribute to the improved glucose metabolism observed.

273

Nevertheless, the FFT was able to alter the phage virions or VLP phageome composition on day 2 compared to the placebo, showing 216 differentially abundant VPs. By day 28 this

276 significant difference disappeared, which indicates the FFT effect was short-lived. Looking at 277 the bacterial hosts of these phages, we found 10 host species that were significantly enriched, 278 of which 9 were more prevalent in the FFT group. One of these bacterial hosts is the butyrate producer Roseburia intestinalis, which has been found to be depleted in MetSyn^{38,39} and 279 contributes to inflammatory signalling inhibition and intestinal barrier repair^{40,41}. Another short-280 281 chain fatty acid producer belonging to the Eisenbergiella species has been associated with 282 increased skeletal muscle mass⁴². Bacteroides fragilis has also been found to be depleted in MetSyn^{43,44}, while *Bacteroides cellulosilyticus*, a cellulose degrader, has been associated with 283 a healthy plant-based diet and found to be depleted in obese individuals^{45,46}. 284

285

In addition, we speculate that the FFT induced virulent interactions between phages and their 286 287 microbe hosts in the first two days after administration, while the phage-microbe interactions appeared more lysogenic/temperate in the placebo group. These results seem to indicate that 288 either the donor phages managed to infect the bacteria from the recipient and lyse them, or 289 that the introduction of novel donor phages induced pre-existing prophages. As the number of 290 291 previously unobserved VLP VPs increased on day 2, while donor-shared VLP VPs did not, we 292 hypothesize the latter is more likely. It could be that some non-phage element of the FFT, such as fructose⁴⁷ or a phage-derived peptide⁴⁸, prompted integrated phages to excise from their 293 294 bacterial hosts. Otherwise, it could also be that increased infection of bacteria by donorderived phages caused lower bacterial abundance, resulting in higher phage lysis rates, in 295 line with the piggyback the winner model of phage-host interactions⁴⁹. Following this 296 hypothesis further, growth of (some) bacterial species after the laxative treatment could have 297 298 caused increased lysogeny among the phageomes in the placebo group.

299

300 Interestingly, changes in bacterial and viral diversity over time were similar between both 301 groups. While we did observe a small, non-significant increase in the abundance of VPs shared with the donor in the WGS phageome, this abundance decreased non-significantly 302 303 within the VLP phageome. This can in part be explained by the large increase in new phages within the VLP phageome (50-60%), which was bigger compared to the increase within the 304 WGS phageome (~15%). The increase in new phages indicates that the phageome was 305 306 perturbed, leading to an accelerated genomic recombination that stimulated phage evolution. 307 However, since this happened in both groups, we hypothesize that this is, in part, an effect of 308 the laxative pre-treatment. This laxative treatment could have removed pre-existing donor-309 shared VPs, and, by washing away part of the host bacteria, could have reduced the probability of donor phages infecting their host. 310

312 This study has several limitations. The small sample size and large heterogeneity within the MetSyn study population hindered identification of significant differences between the groups. 313 The lack of a large FFT effect could also be explained by the use of the laxative pre-treatment, 314 which reduced the number of potential hosts for the transplanted phages. In addition, we 315 316 speculate that the use of laxative prior to the OGTT reduced the fasting insulin levels and associated HOMA-IR values at baseline, which was observed in both groups, independent of 317 the intervention. Therefore, for future studies with FFT, we would highly recommend to omit 318 319 this step. In addition, pooling of donor phages and matching donors and recipients, thereby 320 increasing the diversity and likelihood of a phage-host match, could further improve the efficacy of the FFT. Due the ethical reasons, we had to keep the production of the 321 bacteriophage transplant simple and straightforward, which is why we performed an FFT 322 323 instead of an FVT in this human intervention study. Therefore, we cannot completely rule out any effect of other compounds present in the filtrate besides the phages, such as bacterial 324 debris, metabolites and antimicrobial peptides. In line, we performed tangential flow filtration 325 326 with sterile, single-use cassettes with a 0.2 µm membrane to reduce the potential risk of cross-327 contamination between donors. However, not all phages may pass through these pores and 328 a pore size of 0.45 µm will result in higher phage titres, as has been described previously⁵⁰. 329 Finally, since we only included Dutch European subjects, the generalizability of our results to 330 other populations is limited.

331

Besides above-mentioned suggestions for future FFT studies, future research should focus 332 333 on targeting specific bacteria with phages to get a better mechanistic understanding of how 334 bacterial communities are changed upon phage predation and how these changes could affect disease phenotypes. One example of specific phages targeting pathogenic bacteria is the 335 phage cocktail developed to treat recurrent *Clostridioides difficile* infections⁵¹. Another 336 337 interesting target are the *Lactobacillaceae* that are thought to produce ethanol and thereby contribute to non-alcoholic fatty liver disease (NAFLD)⁵². It should be noted that such precision 338 therapy might be very efficient at clearing a specific pathogen, but will unlikely restore any 339 underlying microbial dysbiosis. Therefore, a combination of endogenous phages to modulate 340 a complete microbiome should be further studied, e.g., by matching donors and recipients 341 342 based on their phageome and bacteriome composition, respectively.

343

In conclusion, this is a first double-blind, randomized, placebo-controlled trial in which we performed an FFT in human individuals with MetSyn. We provide evidence that gut phages from a healthy donor can be safely administered to transiently alter the gut microbiota of recipients. This study provides a critical basis for follow-up studies, which should better match donors and recipients based on their bacteriome and phageome composition.

349

350 METHODS

351 Study design

We set up a prospective, double-blinded, randomised, placebo-controlled intervention study 352 353 that was performed in our academic hospital. After passing screening, 24 subjects with 354 MetSyn were randomised to receive a sterile FFT from a lean healthy donor or a placebo 355 transplant. Block randomization with stratification for age and sex was used, while both 356 participants and researcher were blinded for the intervention. Prior to the intervention and after 28 days at follow-up, subjects underwent an OGTT to assess their glucose metabolism. In 357 addition, a week prior to until one week after intervention, subjects monitored their blood 358 glucose using a flash glucose monitoring device (Freestyle Libre). Fecal samples were 359 360 collected at multiple timepoints between baseline and follow-up to study dynamic changes in the microbiome. Finally, during every study visit a medical exam was conducted in addition to 361 blood plasma collection to assess the safety of the intervention. Figure 1A provides a 362 schematic overview of the study. 363

364

365 Study subjects

Study participants were all European Dutch, overweight (body mass index (BMI) ≥ 25 kg/m²) subjects between 18 and 65 years of age and had to meet the National Cholesterol Education Program (NCEP) criteria for the metabolic syndrome³¹. Main exclusion criteria were the use of any medication, illicit drug use, smoking, or alcohol abuse in the past 3 months, as well as a history of cardiovascular, gastrointestinal, or immunological disease. Table S4 summarises all in- and exclusion criteria.

372

373 Donor screening

Faeces donors were lean healthy European Dutch subjects who were thoroughly screened 374 according to the guidelines of the European FMT Working Group⁵³. Screening of potential 375 donors was performed in a stepwise manner as previously published³². Briefly, potential 376 377 donors first completed an extensive screening questionnaire. If they passed this stage, their faeces were screened for pathogenic parasites. When negative, several faecal samples were 378 379 screened for presence of pathogenic bacteria, viruses, and multidrug resistant organisms 380 (MDROs), as well as the level of calprotectin. Donors screened after May 2020 were 381 additionally screened for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)⁵⁴. 382 In addition, blood was collected for serological testing and to screen for an abnormal liver or renal function or an impaired immunity. When donors passed this screening, they were 383 allowed to donate faeces for a period of 6 months. Table S5 lists the specific in- and exclusion 384 385 criteria for faeces donors. Every two months, active donors underwent a short rescreening,

386 which included, among others, screening for MDROs and SARS-CoV-2. In addition, before

- every donation, donors had to complete a shortened questionnaire to confirm their eligibility.
- 388 We matched donors and recipients based on their gender and whether they have had a prior
- infection with cytomegalovirus or Epstein–Barr virus.
- 390

391 Sterile faecal filtrate production and administration

392 Production of the sterile faecal filtrate started the day before administration to the MetSyn 393 subjects. First, 50 g of stool was collected from a screened donor, which was homogenized with 500 ml sterile saline. Large particles were filtered from the faecal suspension using double 394 sterile gauzes. Most of the bacteria were removed in two subsequent centrifugation steps, in 395 which the suspension was spun for 1 hour at 10.000 x g. Finally, the supernatant was filtered 396 397 through a sterile 0.2 µm membrane using a tangential flow filtration device (Vivaflow 50). Production of the filtrate from donor stool was performed within 6 hours and took, on average, 398 334 minutes (SD = 27). The filtrate was stored overnight in a fridge until administration. The 399 400 production is depicted in figure S3A.

401

The sterile faecal filtrate was administered to the patient via a nasoduodenal tube. The day prior to the administration, subjects were asked to clean their bowel using a laxative (Klean-Prep®, Norgine B.V.), which is a standard pre-treatment for FMT procedures in our hospital. Nasoduodenal tubes were placed with the help of a Cortrak®2 enteral access system (Avanos Medical Inc.), making sure the nasoduodenal tube was correctly positioned. The faecal filtrate was slowly infused with a 60 ml syringe, on average 300 ml during a 15-20 min period. Figure S3B provides a schematic overview of the FFT procedure.

409

We confirmed the absence of bacteria from the faecal filtrate with a qPCR for the bacterial 16S rRNA gene as previously described⁵⁵, showing a 10⁵-fold decrease in bacterial DNA (figure S3C). We further confirmed this by culturing of the faecal filtrate using Biosart® 100 monitors (Sartorius). 100 ml of faecal filtrate was filtered and the cellulose nitrate membranes were incubated on petri dishes with Columbia agar + 5% sheep blood (bioMérieux) for two days at 37°C under both aerobic and anaerobic conditions. We did not observe any colonyforming units in 100 ml of faecal filtrate (results not shown).

417

418 Outcomes

The primary outcome was change in glucose metabolism, as determined by the total area under the curve (AUC) for glucose excursion during the OGTT. Secondary outcomes related to glucose metabolism were changes in fasting glucose, insulin, HOMA-IR, and HbA1c between baseline and follow-up after 28 days, as well as changes in glucose variability

423 measured by CGM a week before and after intervention. Other secondary outcomes were the 424 dynamic changes in gut bacteriome and virome populations following FFT or placebo 425 intervention and the comparison of phage composition between lean donors and subjects with 426 MetSyn. Finally, we assessed the safety of the FFT as determined by the occurrence of 427 (serious) adverse events, physical exam, and several blood parameters for renal and liver 428 function and inflammation.

429

430 Sample size calculation

Based on previous data from our group in which individuals with MetSyn received an FMT^{28,29}, and the hypothesis that a faecal phage transplant can be equally effective as a traditional FMT^{25–27,30}, we assumed a 15% improvement in glucose tolerance upon FFT. With a two-sided 5% significance level and a power of 80%, a sample size of 12 patients per group was necessary, given an anticipated dropout rate of 10%. To recruit 24 individuals with MetSyn, we anticipated a 12-month inclusion period.

437

438 Oral glucose tolerance test

For the OGTT, overnight fasted subjects ingested a standardized glucose solution (75g).
Blood was drawn from an intravenous catheter at baseline and 15, 30, 45, 60, 90, and 120
minutes after ingestion. Both blood serum and plasma were aliquoted and stored at -80°C.
From these aliquots we measured glucose and C-peptide. In addition, additional blood
samples collected at baseline were used to measure fasted glucose and insulin, HbA1c and
the clinical safety parameters for renal/liver function and inflammation.

445

446 **Continuous glucose monitoring**

447 To reduce the study burden and prevent daily finger pricks, we used a continuous glucose 448 monitoring device (Freestyle Libre) to monitor blood glucose, which allowed subjects to perform all normal activities while wearing the sensor. Subjects were taught to subcutaneously 449 450 implant the CGM sensor and were instructed to extract the data from the sensor at least every 8 hours. One week prior to the intervention subjects started to monitor their glucose until one 451 week after the intervention. Compliance among participants was good, with a median 100% 452 453 (range 76-100%) of data correctly collected, during a median period of 14 (range 11-27) days 454 with a median 1350 (range 1043-2617) sensor readings. During that same period, participants 455 were asked to record their diet using an online food diary (Eetmeter from the 456 Voedingscentrum)⁵⁶. At the follow-up visit, data from the CGM scanner were exported and analysed with a previously published R package for CGM data analysis⁵⁷. 457

458

459 Faeces collection

The day before the intervention and 2, 4, 7, 14, and 28 days thereafter, subjects were asked to collect several faecal samples. Faeces were collected by participant in stool collection tubes, which were directly stored in a freezer at home inside a safety bag. In addition, participants registered the time, date, and consistency of the collected faeces according to the Bristol Stool Chart. At the baseline and follow-up visits, these faecal samples were transported to the hospital frozen, where they were directly stored at -80°C until the end of the study.

466

467 Bacteriome and virome sequencing

To study the bacteriome and virome, we performed whole genome shotgun (WGS) sequencing. From the stored frozen faeces samples, total genomic DNA was extracted using a repeated bead beating method as described previously³³. Libraries for shotgun metagenomic sequencing were prepared using the NEBNext Ultra II Library prep kit (New England Biolabs Cat#E7645L) and sequenced on an Illumina HiSeq instrument with 150 bp paired-end reads and 6 Gb data/sample at Novogene (Cambridge, United Kingdom). Figure S3D summarises the sequencing and bioinformatics pipeline used.

475

476 VLP sequencing

477 To study phage virions, we isolated the faecal VLP fraction and sequenced dsDNA phages as 478 previously described¹⁹. Briefly, the VLPs were extracted from 500 mg of faeces using highspeed centrifugation followed by filtration through a 0.45 µm membrane. Any free-DNA debris 479 was digested prior to lysing the VLPs, whereafter the DNA was purified using a two-step 480 phenol/chloroform extraction protocol. Finally, the DNA was purified using the DNeasy 481 Blood&Tissue kit (Qiagen Cat#69506) according to the manufacturer's protocol. Library 482 preparation was done with the NEBNext Ultra II FS DNA library prep kit (New England Biolabs 483 Cat#E7805L) and the NEBNext Multiplex Oligos for Illumina dual indexes (New England 484 485 Biolabs Cat#E7600S) according to manufacturer's instructions. Quality and concentration of the VLP libraries were assessed with the Qubit dsDNA HS kit (ThermoFisher Cat#Q32854) 486 487 and with the Agilent High Sensitivity D5000 ScreenTape system (Agilent Technologies). Libraries were sequenced using 2x150 bp paired-end chemistry on an Illumina NovaSeq 6000 488 489 platform with the S4 Reagent Kit v1.5, 300 cycles (Illumina Cat#20028312).

490

491 Sequence assembly

Sequencing resulted in an average of 21.7 ± 3.5 M reads per WGS sample (median: 22.4 M reads), and 23.6 ± 18.3 M per VLP sample (median: 18.1 M reads). Before assembly, reads belonging to the same participant were concatenated. Adapter sequence removal and read trimming were performed with fastp v0.23.2 (option –detect_adapter_for_pe)⁵⁸. As previously recommended⁵⁹, reads were then error corrected with tadpole (options mode=correct, ecc=t,

497 prefilter=2), and deduplicated with clumpify (options dedupe=t, optical=t, dupedist=12000),

both from bbmap v38.90 (<u>https://igi.doe.gov/data-and-tools/bbtools</u>). High-quality reads from

499 WGS samples were then cross-assembled per participant using metaSPAdes v3.15.5⁶⁰

(option --only-assembler). Due to their greater complexity, VLP reads were assembled with
 MEGAHIT v1.2.9⁶¹.

502

503 Viral sequence recognition and clustering

To identify viral sequences among the WGS and VLP assemblies, contigs longer than 5000 504 bp were analyzed with virsorter v2.2.3⁶² (option --exclude-lt2gene) and checkv v1.0.1⁶³. 505 Contigs were taken to be of viral origin if at least one of the following criteria was true: checky 506 identified at least one viral gene, VirSorter2 gave a score of at least 0.95, VirSorter2 identified 507 at least 2 viral hallmark genes, checkv identified no viral or bacterial genes. The resulting viral 508 sequences were then deduplicated at 100% with bbdupe from bbmap v38.90 (option 509 minidentity=100). This resulted in a non-redundant database of 50.724 viral contias, which 510 were subsequently clustered at 90% average nucleotide identity (ANI) into viral populations 511 (VPs) using blastn all-vs-all searches with BLAST v2.12.0+64. The longest contigs in each VP 512 were further clustered into viral clusters (VCs) by vContact2 v0.11.3⁶⁵. Since the conclusions 513 514 of the analyses were identical regardless of whether they were performed with VPs or VCs, 515 only VP-level analyses were reported.

516

517 Viral read depth determination

518 Viral relative abundance was determined by mapping high-quality reads from each sample 519 (i.e., one mapping per participant and time-point) against non-redundant viral sequences with bowtie2 v2.4.2⁶⁶. Following earlier recommendations⁶⁷, contigs were considered to be present 520 if at least 75% of their bases were covered by at least 1 read mapped with over 90% ANI. To 521 522 determine this, reads mapping with less than 90% ANI were removed from alignments with filter --min-read-percent-identity 90. 523 coverm v0.6.1 (option https://github.com/wwood/CoverM), and coverage was determined with bedtools genomecov 524 v2.27.1⁶⁸ (option -max 1). Read counts per contigs were then determined with samtools 525 idxstats v1.15.1⁶⁹, and those with a horizontal coverage of <75% were set to zero. Read counts 526 527 and contig lengths were summed per VP, and reads per kilobase per million mapped reads 528 (RPKM) values were calculated to take differential contig lengths.

529

530 Bacterial community profiling and binning

Bacterial population compositions of WGS samples were profiled per participant and time point
with mOTUs v3.0.3⁷⁰. Binning contigs into metagenome assembled genomes (MAGs) was
done per participant. First, high quality reads from each time-point were mapped to cross-

assembled contigs of at least 2500 bp with bowtie2 v2.4.2. Read depth tables were then constructed with jgi_summarize_bam_contig_depths v2.15, and contigs were binned with metabat2 v2:2.15⁷¹. Completion and contamination of putative MAGs were then determined using checkm v1.2.1⁷² and, like was previously done⁷³, MAGs were considered for further analysis if completeness - (5 x contamination) was at least 50. Taxonomy of such MAGs was determined with GTDB-Tk v2.1.1⁷⁴ using the R207-v2 database package. This resulted in a database of 3011 MAGs with an assigned taxonomy.

541

542 **Determining phage-host links**

543 Viral sequences were linked to bacterial MAGs in two ways. Firstly, if a viral contig was 544 contained within a MAG, it was considered to be a prophage. Secondly, viral contigs were 545 linked to MAGs using CRISPR spacer hits. For this, CRISPR spacer arrays were identified 546 among MAGs using CRISPCasFinder v4.2.20⁷⁵. CRISPR spacers between 20 and 30 bp in 547 length were then matched to viral contigs through a blastn search with BLAST v2.12.0+ 548 (options -task blastn-short). Spacer hits were finally filtered for those with 5 or fewer 549 mismatches.

550

551 Statistical analyses

552 Richness, α -diversities, principal component analysis (PCA), and principal response curves (PRC) were all calculated with the vegan R package⁷⁶. For richness and α -diversity RPKM 553 values were used, while PCAs and PRCs used centered log ratio (clr)-transformed data so as 554 to account for the compositionality of the data⁷⁷. Before clr-transformation, VPs of low 555 abundance and prevalence were removed by removing those with total RPKM of <100 over 556 all samples, as well as those with RPKM values of >20 in less than 10% of samples. 557 Significance levels of PCAs were calculated with a permutational analysis of variance 558 559 (PERMANOVA) test, as implemented in the vegan R package v2.6-4 and were controlled for age and sex. For the PRC-analysis, the permutest function was used to calculate significance. 560 561 Both PERMANOVA and permutest used 1000 permutations. p-values were adjusted for multiple testing using the Benjamini-Hochberg approach where necessary. General linear 562 models were constructed with the glmmPQL function from the MASS R package v7.3-58.1 563 564 with the age, sex, day, group, and day: group as fixed effects and participants as random effect.

565

566 Differential abundance

567 Differential abundance of VPs among VLP samples on day 2 was determined with ANCOM-568 BC v1.2.2⁷⁸. Input of ANCOM-BC consisted of the raw read counts summed per VP in each 569 sample, because this method has its own internal data normalizations to account estimated 570 sample fractions. ANCOM-BC was run on VPs with at least 20 reads reported in at least 10%

571 of samples. To account for the relatively small sample sizes, structural zero discovery was 572 turned on but the usage of the asymptotic lower bound turned off⁷⁸. Differential abundance was corrected for the effects of age and sex. The number of differentially abundant (DA) VPs 573 was then determined per host species. Enrichment of host species among DA VPs was 574 575 calculated using a hypergeometric test as implemented in the phyper R function, with the number of DA VPs infecting a given species-1 as g, the total number of VPs in the dataset 576 infecting the same species as m, the total number of VPs with host-m as n, the total number 577 578 of DA VPs as k, and lower.tail set to FALSE.

579

580 Phage-host interactions

To determine the dynamics of phage-bacterium interaction across the entire population, the change in relative abundance between days 0 and 2, 2 and 28, and 0 and 28 were determined for all VPs with a host and all MAGs with a known phage. The resulting values were then averaged for both VPs and MAGs at the species level, after which Spearman correlation coefficients were calculated.

586

587 Supplementary material

- 588 Figure S1: Recruitment of individuals with MetSyn and stool donors.
- 589 Figure S2: Principal component analyses of viral populations.
- 590 Figure S3: Methods of FFT production and sequencing pipeline.
- 591 Table S1: Baseline dietary intake of participants.
- 592 Table S2: Results from the continuous glucose monitoring devices.
- 593 Table S3: Differentially abundant viral populations between the FFT and placebo groups.
- Table S4: In- and exclusion criteria for study participants.
- 595 Table S5: In- and exclusion criteria for faeces donors.
- 596

597 Acknowledgements

598 We want to thank Aline Fenneman, Klaartje de Bruin and Melhandanie Benard for their help 599 with stool donor recruitment and screening. In addition, we thank Veera Houttu, Ulrika

- 600 Boulund, Kim Dzobo and Torsten Scheithauer for performing the randomization to guarantee
- blinding of the investigator and volunteer. We would also like to thank Ana Gerós, Yannick
 van Schajik and Stephanie Handana for their help in setting up the faecal filtrate production
- and optimisation. We are grateful for the help of the gastroenterology department of the
- and optimisation. We are grateful for the help of the gastroenterology department of the
- Amsterdam UMC, location AMC, for their support with the Cortrak®2 enteral access system.
- 605 We also like to acknowledge the Microbiota Centre Amsterdam for their help with the DNA
- 606 isolation of the faecal samples and the Genomics core of the Amsterdam UMC, location

- AMC, for their advice on the whole genome shotgun sequencing. Finally, we are most
- 608 grateful for the volunteers who participated in this clinical pilot study.
- 609

610 Author contributions

- 611 HH and MN conceived the research idea and designed the study; KW performed the clinical
- study; KW and TPMS processed the samples in the laboratory; PAdJ, KW and IA performed
- data analysis; KW and PAdJ wrote the first draft of the manuscript; All authors contributed to
- 614 manuscript revision, read and approved the submitted version.
- 615

616 Funding

KW was supported by a Novo Nordisk Foundation CAMIT grant 2018 (28232) to MN and a 617 618 Diabetes II Breakthrough grant (459001008) to HH. PAdJ en TPMS were supported by DDRF Senior fellowship (2019.82.004) to HH. IA was supported through a Le Ducq consortium grant 619 (17CVD01) to MN. MN was supported by a personal ZONMW-VICI grant 2020 620 (09150182010020) and a Le Ducq consortium grant (17CVD01). HH was supported by a 621 622 Senior Fellowship of the Dutch Diabetes Research Foundation (2019.82.004). The funders 623 had no role in the study design, the collection, analysis, and interpretation of data, the writing 624 of the report, and the decision to submit the article for publication.

625

626 Competing interests

627 MN is founder and scientific advisors of Caelus Health, however none of this bears any 628 relevance to the content of the current paper. KW, PAdJ, TPMS, IA, EMK, and HH report no 629 conflict of interest.

630

631 Patient and public involvement statement

Patients were involved in the assessment of the grant proposals for this study by the Dutch Diabetes Research Foundation (Diabetes II Breakthrough grant (459001008) and Senior Fellowship (2019.82.004)). Moreover, the patient panel advised on the patient burden of the clinical study. Moreover, patients were involved in the ethical approval of this study (as part of the ethics committee). Once the trial has been published, participants are informed of the results in a letter suitable for a non-specialist audience.

638

639 Ethics approval and informed consent statement

640 This study involves human participants and was approved by the Medical Research Ethics

641 Committee Academic Medical Center Amsterdam. Both participants and faeces donors gave

- informed consent to participate in the study before taking part. The study was registered at
- the Dutch National Trial Register (NTR) under NL8289. This registry does not exist anymore

and all data has been added unaltered to the Dutch Trial Register (LTR) under https://clinicaltrialregister.nl/en/trial/26916. While these data are automatically included in the

644

645

International Clinical Trial Registry Platform (ICTRP), thereby fulfilling the requirement of 646 prospective registration as required by the International Committee of Medical Journal Editors 647 648 (ICMJE), it was unfortunately no longer possible to adjust the data. 649 650 Data availability statement The sequencing data generated in this study have been deposited in the European 651 Nucleotide Archive database under accession code: PRJEB60691. The data are freely 652 653 available without restriction. 654 655 Code availability statement All used software is freely available. In the methods section the specific versions and 656 settings are described. No custom software was developed for this project. 657 658 659 References Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J 660 1. Clin Invest. 2019 Oct 1;129(10):4050-7. 661 662 2. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015 Jan;16(1):1–12. 663 3. Gurka MJ, Guo Y, Filipp SL, DeBoer MD. Metabolic syndrome severity is significantly 664 associated with future coronary heart disease in Type 2 diabetes. Cardiovasc 665 Diabetol. 2018 Jan 19;17(1):17. 666 667 4. Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van 668 Raalte DH, et al. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes. Front Immunol. 2020;11:571731. 669 670 5. Ussar S, Griffin NW, Bezy O, Fujisaka S, Vienberg S, Softic S, et al. Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to 671 Obesity and Metabolic Syndrome. Cell Metab. 2015 Sep;22(3):516-30. 672 Zuppi M, Hendrickson HL, O'Sullivan JM, Vatanen T. Phages in the Gut Ecosystem. 673 6. Front Cell Infect Microbiol. 2021;11(January):822562. 674 Shkoporov AN, Hill C. Bacteriophages of the Human Gut: The "Known Unknown" of 7. 675 the Microbiome. Cell Host Microbe [Internet]. 2019;25(2):195-209. Available from: 676 https://doi.org/10.1016/j.chom.2019.01.017 677 Gregory AC, Zablocki O, Zayed AA, Howell A, Bolduc B, Sullivan MB. The Gut Virome 678 8. Database Reveals Age-Dependent Patterns of Virome Diversity in the Human Gut. 679 680 Cell Host Microbe. 2020 Nov 11;28(5):724-740.e8. Manuscript PIMMS – Version 6.0 – 23/02/2023 Page 19 of 29

Marbouty M, Thierry A, Millot GA, Koszul R. MetaHiC phage-bacteria infection
network reveals active cycling phages of the healthy human gut. Elife. 2021 Feb
26;10.

- de Jonge PA, Nobrega FL, Brouns SJJ, Dutilh BE. Molecular and Evolutionary
 Determinants of Bacteriophage Host Range. Trends Microbiol. 2019 Jan;27(1):51–63.
- Breitbart M, Bonnain C, Malki K, Sawaya NA. Phage puppet masters of the marine
 microbial realm. Nat Microbiol. 2018 Jul;3(7):754–66.
- Kuzyakov Y, Mason-Jones K. Viruses in soil: Nano-scale undead drivers of microbial
 life, biogeochemical turnover and ecosystem functions. Soil Biol Biochem. 2018
 Dec;127:305–17.
- Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, et al.
 Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and
 Colitis. Cell Host Microbe. 2019;25(2):285-299.e8.
- Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Diseasespecific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015
 Jan 29;160(3):447–60.
- Adiliaghdam F, Amatullah H, Digumarthi S, Saunders TL, Rahman R-U, Wong LP, et
 al. Human enteric viruses autonomously shape inflammatory bowel disease
 phenotype through divergent innate immunomodulation. Sci Immunol. 2022 Apr
 8;7(70):eabn6660.
- 16. Nakatsu G, Zhou H, Wu WKK, Wong SH, Coker OO, Dai Z, et al. Alterations in
 Enteric Virome Are Associated With Colorectal Cancer and Survival Outcomes.
 Gastroenterology. 2018 Aug;155(2):529-541.e5.
- 17. Chen Q, Ma X, Li C, Shen Y, Zhu W, Zhang Y, et al. Enteric Phageome Alterations in
 Patients With Type 2 Diabetes. Front Cell Infect Microbiol. 2020;10:575084.
- Manrique P, Zhu Y, van der Oost J, Herrema H, Nieuwdorp M, de Vos WM, et al. Gut
 bacteriophage dynamics during fecal microbial transplantation in subjects with
 metabolic syndrome. Gut Microbes. 2021;13(1):1–15.
- 19. de Jonge PA, Wortelboer K, Scheithauer TPM, van den Born B-JH, Zwinderman AH,
- Nobrega FL, et al. Gut virome profiling identifies a widespread bacteriophage family
 associated with metabolic syndrome. Nat Commun. 2022;13(1):3594.
- Hsu BB, Gibson TE, Yeliseyev V, Liu Q, Lyon L, Bry L, et al. Dynamic Modulation of
 the Gut Microbiota and Metabolome by Bacteriophages in a Mouse Model. Cell Host
 Microbe [Internet]. 2019;25(6):803-814.e5. Available from:
- 715 https://doi.org/10.1016/j.chom.2019.05.001
- 716 21. Manohar P, Tamhankar AJ, Lundborg CS, Nachimuthu R. Therapeutic
- 717 Characterization and Efficacy of Bacteriophage Cocktails Infecting Escherichia coli,

718		Klebsiella pneumoniae, and Enterobacter Species. Front Microbiol. 2019;10:574.
719	22.	Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, et al. Synergy
720		between the Host Immune System and Bacteriophage Is Essential for Successful
721		Phage Therapy against an Acute Respiratory Pathogen. Cell Host Microbe. 2017 Jul
722		12;22(1):38-47.e4.
723	23.	Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies M-A, et al.
724		Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low
725		impact on microbiota composition. Environ Microbiol. 2016 Jul 28;18(7):2237–45.
726	24.	Mai V, Ukhanova M, Reinhard MK, Li M, Sulakvelidze A. Bacteriophage
727		administration significantly reduces Shigella colonization and shedding by Shigella-
728		challenged mice without deleterious side effects and distortions in the gut microbiota.
729		Bacteriophage. 2015;5(4):e1088124.
730	25.	Lin DM, Koskella B, Ritz NL, Lin D, Carroll-Portillo A, Lin HC. Transplanting Fecal
731		Virus-Like Particles Reduces High-Fat Diet-Induced Small Intestinal Bacterial
732		Overgrowth in Mice. Front Cell Infect Microbiol. 2019;9(October):1–11.
733	26.	Draper LA, Ryan FJ, Dalmasso M, Casey PG, McCann A, Velayudhan V, et al.
734		Autochthonous faecal viral transfer (FVT) impacts the murine microbiome after
735		antibiotic perturbation. BMC Biol. 2020;18(1):173.
736	27.	Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al.
737		Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile
738		Infection. Gastroenterology [Internet]. 2017;152(4):799–811. Available from:
739		http://dx.doi.org/10.1053/j.gastro.2016.11.010
740	28.	Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, et al.
741		Transfer of intestinal microbiota from lean donors increases insulin sensitivity in
742		individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-916.e7.
743	29.	Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra A V., Udayappan SD, et al.
744		Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is
745		Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017 Oct
746		3;26(4):611-619.e6.
747	30.	Rasmussen TS, Mentzel CMJ, Kot W, Castro-Mejía JL, Zuffa S, Swann JR, et al.
748		Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in
749		a murine model. Gut. 2020 Dec 12;69(12):2122–30.
750	31.	Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al.
751		Diagnosis and management of the metabolic syndrome: an American Heart
752		Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation.
753		2005 Oct 25;112(17):2735–52.
754	32.	Bénard M V., de Bruijn CMA, Fenneman AC, Wortelboer K, Zeevenhoven J, Rethans

755		B, et al. Challenges and costs of donor screening for fecal microbiota
756		transplantations. PLoS One. 2022;17(10):e0276323.
757	33.	Deschasaux M, Bouter KE, Prodan A, Levin E, Groen AK, Herrema H, et al. Depicting
758		the composition of gut microbiota in a population with varied ethnic origins but shared
759		geography. Nat Med. 2018;24(10):1526–31.
760	34.	Gregory AC, Zayed AA, Conceição-Neto N, Temperton B, Bolduc B, Alberti A, et al.
761		Marine DNA Viral Macro- and Microdiversity from Pole to Pole. Cell. 2019 May
762		16;177(5):1109-1123.e14.
763	35.	Li Y-T, Cai H-F, Wang Z-H, Xu J, Fang J-Y. Systematic review with meta-analysis:
764		long-term outcomes of faecal microbiota transplantation for Clostridium difficile
765		infection. Aliment Pharmacol Ther. 2016 Feb;43(4):445–57.
766	36.	Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for
767		Clostridium difficile-associated diarrhoea: a systematic review of randomised
768		controlled trials. Med J Aust. 2017 Aug 21;207(4):166–72.
769	37.	Nguyen TLA, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for
770		human gut microbiota research? Dis Model Mech. 2015 Jan;8(1):1–16.
771	38.	Qin Q, Yan S, Yang Y, Chen J, Li T, Gao X, et al. A Metagenome-Wide Association
772		Study of the Gut Microbiome and Metabolic Syndrome. Front Microbiol.
773		2021;12:682721.
774	39.	Zhang C, Ma K, Nie K, Deng M, Luo W, Wu X, et al. Assessment of the safety and
775		probiotic properties of Roseburia intestinalis: A potential "Next Generation Probiotic".
776		Front Microbiol. 2022;13:973046.
777	40.	Zhao C, Bao L, Qiu M, Wu K, Zhao Y, Feng L, et al. Commensal cow Roseburia
778		reduces gut-dysbiosis-induced mastitis through inhibiting bacterial translocation by
779		producing butyrate in mice. Cell Rep. 2022 Nov 22;41(8):111681.
780	41.	Ruan G, Chen M, Chen L, Xu F, Xiao Z, Yi A, et al. Roseburia intestinalis and Its
781		Metabolite Butyrate Inhibit Colitis and Upregulate TLR5 through the SP3 Signaling
782		Pathway. Nutrients. 2022 Jul 25;14(15).
783	42.	Sugimura Y, Kanda A, Sawada K, Wai KM, Tanabu A, Ozato N, et al. Association
784		between Gut Microbiota and Body Composition in Japanese General Population: A
785		Focus on Gut Microbiota and Skeletal Muscle. Int J Environ Res Public Health. 2022
786		Jun 17;19(12).
787	43.	Haro C, Garcia-Carpintero S, Alcala-Diaz JF, Gomez-Delgado F, Delgado-Lista J,
788		Perez-Martinez P, et al. The gut microbial community in metabolic syndrome patients
789		is modified by diet. J Nutr Biochem. 2016 Jan;27:27–31.
790	44.	Ermolenko E, Kotyleva M, Kotrova A, Tichonov S, Lavrenova N, Voropaeva L, et al.
791		Consortium of Indigenous Fecal Bacteria in the Treatment of Metabolic Syndrome.

792 Microorganisms. 2022 Aug 5;10(8). 793 45. Li Y, Wang DD, Satija A, Ivey KL, Li J, Wilkinson JE, et al. Plant-Based Diet Index and 794 Metabolic Risk in Men: Exploring the Role of the Gut Microbiome. J Nutr. 2021 Sep 795 4;151(9):2780-9. 796 46. Chen H, Tang N, Ye Q, Yu X, Yang R, Cheng H, et al. Alternation of the gut 797 microbiota in metabolically healthy obesity: An integrated multiomics analysis. Front 798 Cell Infect Microbiol. 2022;12:1012028. 799 47. Oh J-H, Alexander LM, Pan M, Schueler KL, Keller MP, Attie AD, et al. Dietary 800 Fructose and Microbiota-Derived Short-Chain Fatty Acids Promote Bacteriophage Production in the Gut Symbiont Lactobacillus reuteri. Cell Host Microbe. 2019 Feb 801 802 13;25(2):273-284.e6. 803 48. Erez Z, Steinberger-Levy I, Shamir M, Doron S, Stokar-Avihail A, Peleg Y, et al. Communication between viruses guides lysis-lysogeny decisions. Nature. 2017 Jan 804 26:541(7638):488-93. 805 806 49. Silveira CB, Rohwer FL. Piggyback-the-Winner in host-associated microbial 807 communities. NPJ biofilms microbiomes. 2016;2:16010. 808 50. Castro-Mejía JL, Muhammed MK, Kot W, Neve H, Franz CMAP, Hansen LH, et al. 809 Optimizing protocols for extraction of bacteriophages prior to metagenomic analyses 810 of phage communities in the human gut. Microbiome. 2015 Nov 17;3:64. Fujimoto K, Uematsu S. Phage therapy for Clostridioides difficile infection. Front 811 51. Immunol. 2022;13:1057892. 812 813 52. Meijnikman AS, Davids M, Herrema H, Aydin O, Tremaroli V, Rios-Morales M, et al. 814 Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med. 2022 Oct;28(10):2100-6. 815 816 53. Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, et al. 817 European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017 Apr;66(4):569-80. 818 54. Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, et al. Reorganisation of 819 faecal microbiota transplant services during the COVID-19 pandemic. Gut. 2020 820 Sep;69(9):1555-63. 821 822 55. Jian C, Luukkonen P, Yki-Järvinen H, Salonen A, Korpela K. Quantitative PCR 823 provides a simple and accessible method for quantitative microbiota profiling. PLoS 824 One. 2020;15(1):e0227285. 825 56. Stichting Voedingscentrum Nederland. Eetmeter [Internet]. 2023 [cited 2023 Jan 16]. Available from: https://mijn.voedingscentrum.nl/nl/eetmeter/ 826 827 57. Attaye I, van der Vossen EWJ, Mendes Bastos DN, Nieuwdorp M, Levin E. 828 Introducing the Continuous Glucose Data Analysis (CGDA) R Package: An Intuitive

829		Package to Analyze Continuous Glucose Monitoring Data. J Diabetes Sci Technol.
830		2022 May;16(3):783–5.
831	58.	Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
832		Bioinformatics. 2018 Sep 1;34(17):i884–90.
833	59.	Roux S, Trubl G, Goudeau D, Nath N, Couradeau E, Ahlgren NA, et al. Optimizing de
834		novo genome assembly from PCR-amplified metagenomes. PeerJ. 2019;7:e6902.
835	60.	Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. metaSPAdes: a new versatile
836		metagenomic assembler. Genome Res. 2017 May;27(5):824–34.
837	61.	Li D, Liu C-M, Luo R, Sadakane K, Lam T-W. MEGAHIT: an ultra-fast single-node
838		solution for large and complex metagenomics assembly via succinct de Bruijn graph.
839		Bioinformatics. 2015 May 15;31(10):1674–6.
840	62.	Guo J, Bolduc B, Zayed AA, Varsani A, Dominguez-Huerta G, Delmont TO, et al.
841		VirSorter2: a multi-classifier, expert-guided approach to detect diverse DNA and RNA
842		viruses. Microbiome. 2021 Feb 1;9(1):37.
843	63.	Nayfach S, Camargo AP, Schulz F, Eloe-Fadrosh E, Roux S, Kyrpides NC. CheckV
844		assesses the quality and completeness of metagenome-assembled viral genomes.
845		Nat Biotechnol. 2021 May;39(5):578–85.
846	64.	Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al.
847		BLAST+: architecture and applications. BMC Bioinformatics. 2009 Dec 15;10:421.
848	65.	Bin Jang H, Bolduc B, Zablocki O, Kuhn JH, Roux S, Adriaenssens EM, et al.
849		Taxonomic assignment of uncultivated prokaryotic virus genomes is enabled by gene-
850		sharing networks. Nat Biotechnol. 2019 Jun;37(6):632–9.
851	66.	Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient
852		alignment of short DNA sequences to the human genome. Genome Biol.
853		2009;10(3):R25.
854	67.	Roux S, Emerson JB, Eloe-Fadrosh EA, Sullivan MB. Benchmarking viromics: an in
855		silico evaluation of metagenome-enabled estimates of viral community composition
856		and diversity. PeerJ. 2017;5:e3817.
857	68.	Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic
858		features. Bioinformatics. 2010 Mar 15;26(6):841–2.
859	69.	Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years
860		of SAMtools and BCFtools. Gigascience. 2021 Feb 16;10(2).
861	70.	Milanese A, Mende DR, Paoli L, Salazar G, Ruscheweyh H-J, Cuenca M, et al.
862		Microbial abundance, activity and population genomic profiling with mOTUs2. Nat
863		Commun. 2019 Mar 4;10(1):1014.
864	71.	Kang DD, Li F, Kirton E, Thomas A, Egan R, An H, et al. MetaBAT 2: an adaptive
865		binning algorithm for robust and efficient genome reconstruction from metagenome
		· · · · · · · · · · · · · · · · · ·

866 assemblies. PeerJ. 2019;7:e7359. 867 72. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and 868 metagenomes. Genome Res. 2015 Jul;25(7):1043-55. 869 870 73. Parks DH, Rinke C, Chuvochina M, Chaumeil P-A, Woodcroft BJ, Evans PN, et al. 871 Recovery of nearly 8.000 metagenome-assembled genomes substantially expands the tree of life. Nat Microbiol. 2017 Nov;2(11):1533-42. 872 873 74. Chaumeil P-A, Mussig AJ, Hugenholtz P, Parks DH. GTDB-Tk: a toolkit to classify 874 genomes with the Genome Taxonomy Database. Bioinformatics. 2019 Nov 15;36(6):1925-7. 875 75. Couvin D, Bernheim A, Toffano-Nioche C, Touchon M, Michalik J, Néron B, et al. 876 877 CRISPRCasFinder, an update of CRISRFinder, includes a portable version, enhanced performance and integrates search for Cas proteins. Nucleic Acids Res. 878 2018 Jul 2:46(W1):W246-51. 879 76. Dixon P. VEGAN, a package of R functions for community ecology. J Veg Sci. 2003 880 881 Dec 9;14(6):927-30. 882 77. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome Datasets Are 883 Compositional: And This Is Not Optional. Front Microbiol. 2017;8:2224. 884 78. Lin H, Peddada S Das. Analysis of compositions of microbiomes with bias correction. Nat Commun. 2020 Jul 14;11(1):3514. 885 886

887 Figures and tables

Figure 1: A) Overview of the study. B) Glucose excursions during the oral glucose tolerance 888 test. One person who was randomized to the FFT group had progressed to type 2 diabetes, 889 890 which was not apparent at the time of screening. C) Total area under the curve (AUC) for 891 glucose and **D**) for C-peptide did not significantly differ between the groups. Within both groups there was a small increase in glucose AUC between day 0 and 28, which was nominal 892 significant within the FFT group, although this significance disappeared after correction for 893 multiple testing. E) Insulin resistance (HOMA-IR) measures did not significantly differ between 894 the groups, but significantly increased from day 0 to day 28 in both groups. F) Glucose 895 896 variability, expressed as time between 3.9-10 mmol/L glucose, improved only within the FFT 897 group between day 0 and day 28, which was nominal significant, but disappeared after 898 correcting for multiple testing.

899

Figure 2: A) Overview of the faecal samples used for the bulk metagenomic sequencing (for
 bacteriome and phageome) and the metagenomic sequencing of the viral-like particles (VLP).

902 **B)** The richness (number of observed species) in the bacteriome, phage virions (VLP) and 903 bulk-derived phageome (WGS) from baseline until follow-up at day 28. Though there were no 904 significant differences between the placebo and faecal filtrate group, the richness in the bacteriome reduced slightly after both interventions. A similar trend was observed in the 905 906 phageome (mostly prophages present in bacterial hosts), while the richness in the VLP fraction 907 tended to increase slightly at day 2 for both interventions. C) The alpha-diversity (Shannon 908 index) of the bacteriome, phage virions (VLP) and bulk-derived phageome (WGS) from 909 baseline until follow-up at day 28. Again, no significant differences were found between the 910 interventions. Similar to the richness, the diversity of the bacteriome and phageome slightly decreased directly after the interventions. For the free phages, the diversity decreased slightly 911 in the placebo group, but not in the faecal filtrate group. 912

913

914 Figure 3: A) The percentage of phages that were shared between the donor and recipient within the phageome and **B**) within the phage virions after the faecal filtrate transplantation. 915 916 There was a slight, non-significant increase in the relative abundance of (pro)phages shared 917 with the donor after the intervention, while the relative abundance of phage virions that were 918 shared with the donor slightly decreased. C) The percentage of new phages that were present 919 after the intervention within the bulk-derived phageome and D) within the phage virions. In 920 both, the relative abundance of new phages increased over time and although not significant, 921 this increase was slightly higher in the FFT group.

922

923 Figure 4: A) Principal response curve showing how the FFT group differs from the placebo 924 (set to zero) in the bacteriome, bulk-derived phageome (WGS), and phage virion (VLP) composition. Significance in dispersion over time and at each separate time-point was 925 calculated with permutation tests. B) Principal component analysis of VLP composition after 926 927 centered log-ratio transformation. Large points show the mean of each group. C) Log fold change for all 216 viral populations (VP) indicated as differentially abundant by ANCOM-BC 928 analysis. For legibility, VP names are not shown, these can be found in supplementary table 929 930 S4. D) Bacterial host species of which the phages are enriched among differentially abundant VPs. The first column shows the number of differentially abundant VPs, the second the total 931 932 number of VPs linked to a given host in the dataset, and stars show the level of significance 933 after testing for enrichment with a hypergeometric test. E) splits up the data on the first column 934 of D by participant group.

935

Figure 5: A) Correlations plots showing the change in relative abundance between day 0 and
day 2 of viral populations (VP) versus host bacteria. Each datapoint represents the interactions
between the VPs and metagenome assembled genomes (MAGs) of a particular species within

939 a given sample. Linkages between VPs and MAGs were based on either CRISPR spacer hits 940 or the presence of the VP as a prophage in the MAG. The Spearman correlation coefficient 941 showed that phage-bacterium interactions in FFT samples tended toward antagonism, while those in placebo samples were protagonistic. B) Same as A, but showing the change in 942 943 relative abundance between day 2 and day 28. The Spearman correlation coefficient showed that phage-bacterium interactions in placebo samples were protagonistic. C) Same as A and 944 B, but showing the change in relative abundance between day 0 and day 28. There was no 945 946 overall correlation between changes in abundance of VPs and host MAGs.

947

Supplementary figure S1: A) Recruitment and screening of participants with the metabolic
syndrome. B) Recruitment and screening of healthy donors for the sterile faecal filtrate. BMI
Body Mass Index; D. fragilis = Dientamoeba fragilis; ESBL = extended spectrum betalactamase producer FMT = faecal microbiota transplantation; H. pylori = Helicobacter pylori;
ICF = informed consent form; PPI = proton pump inhibitor; STEC = shigatoxigenic Escherichia
coli.

954

955 Supplementary figure S2: A) Principal component analysis (PCA) of the viral populations 956 (VP) within the phage virions (VLP) and **B)** bulk-derived phageome (WGS) between the 957 subjects with metabolic syndrome in the faecal filtrate (FFT) and placebo groups and the healthy subjects who donated their stool at baseline. There were no differences in overall 958 composition of the (pro)phages between the groups as determined by permutational analysis 959 960 of variance (PERMANOVA). C) PCA of the VPs showing the difference in overall 961 composition between the free phages (VLP) and bulk-derived phageome (WGS), which was statistically significant as determined by PERMANOVA (p = 0.001). 962

963

964 Supplementary figure S3: A) Production of the sterile faecal filtrate started the day before the administration to the MetSyn subjects. First, stool was collected from a healthy, thoroughly 965 966 screened donor, which was homogenized with sterile saline. Large particles were then filtered 967 from the faecal suspension using double sterile gauzes. Most bacteria were pelleted in two subsequent centrifugation steps, in which the suspension was spun for 1 hour at 10.000 RCF. 968 969 The supernatant was then filtered through a sterile 0.2 µm membrane using a tangential flow 970 filtration device (Vivaflow® 50). The filtrate was stored overnight in a fridge until administration. 971 B) The sterile faecal filtrate was administered to the patient via a nasoduodenal tube. The day 972 prior to the administration, subjects were asked to clean their bowel using a laxative, which is 973 a standard pre-treatment for FMT procedures in our hospital. Nasoduodenal tubes were placed with the help of a Cortrak device, making sure the nasoduodenal tube was correctly 974 975 positioned. The faecal filtrate was slowly infused with a 60 ml syringe, on average 300 ml

976 during a 15-20 min period. **C)** We confirmed with a qPCR for the bacterial 16S rRNA gene the 977 absence of bacteria within the faecal filtrate, showing a 10^5-fold decrease in bacterial DNA. 978 We further confirmed the absence of bacteria by culturing the faecal filtrate, observing no 979 colony-forming units in 100 ml of faecal filtrate (results not shown). **D)** Overview of the used 980 pipeline for the microbiome shotgun sequencing and the VLP shotgun sequencing. *MAGs* = 981 *Metagenome-assembled genomes; QC* = *quality control; VLP* = *viral-like particle; WGS* = 982 *whole genome shotgun.*

983

Table 1: Baseline characteristics of MetSyn subjects and lean donors.

Unless otherwise specified, data are reported as mean (SD). Statistical testing between the
placebo and faecal filtrate groups and metabolic syndrome subjects and donors is performed
by independent Mann-Whitney U test for continuous variables and by Chi-square test for
categorical and binary variables. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood
pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = highdensity lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.

991

992 **Table 2:** Differences in clinical safety markers after intervention.

- 993 Unless otherwise specified data are reported as mean (SD). Statistical testing for categorical 994 and binary variables from the adverse events was done by Chi-square tests. Mixed model 995 analyses were used to assess differences between groups and timepoints, whereafter post hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant 996 differences between day 0 and 28 within a treatment group (* = P<0.05). The p-value shows 997 998 the overall effect of treatment on the variable and only when significant, the adjusted p-values from the post hoc tests are shown. EA = adverse event; AF = alkaline phosphatase; ALAT = 999 1000 alanine aminotransferase; ASAT = aspartate aminotransferase; eGFR = estimated glomerular 1001 filtration rate: GGT = gamma-glutamyltransferase: MCV = mean corpuscular volume.
- 1002

Table 3: Changes in physical and metabolic variables after intervention.

1004 Unless otherwise specified, data are reported as mean (SD). Mixed model analyses were used 1005 to assess differences between groups and timepoints, whereafter post hoc analyses were 1006 performed with Bonferroni correction. Stars indicate statistical significant differences between day 0 and 28 within a treatment group (* = p<0.05; ** = p<0.005). The p-value shows the 1007 1008 overall effect of treatment on the variable and when significant, the adjusted p-values from the 1009 post hoc tests are shown. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-1010 density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein. 1011

- 1013 **Supplementary table S1:** Baseline dietary intake of participants.
- 1014 Data are reported as mean (SD). Statistical testing between the placebo and fecal filtrate 1015 groups is performed by independent Mann-Whitney U test.
- 1016

1017 **Supplementary table 2:** Results from the continuous glucose monitoring devices.

Unless otherwise specified data are reported as mean (SD). Mixed model analyses were used to assess differences between groups and timepoints, whereafter post hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant differences between day 0 and 28 within a treatment group (* = p<0.05). The p-value shows the overall effect of treatment on the variable and only when significant, the adjusted p-values from the post hoc tests are shown. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-density lipoprotein;

1025 LDL = low-density lipoprotein; CRP = C-reactive protein.

1026

Supplementary table S3: Differentially abundant viral populations within the VLP phageomeon day 2.

1029

1030 **Supplementary table S4:** In- and exclusion criteria for study participants.

Abbreviations: CVA = cerebrovascular accident; HDL = high-density lipoprotein; HIV = human immunodeficiency viruses; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; MI = myocardial infarction; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

1035

1036 **Supplementary table S5:** In- and exclusion criteria for faeces donors.

1037 Abbreviations: AF = alkaline phosphatase; ALAT = alanine aminotransferase; ASAT = 1038 aspartate aminotransferase; CMV = cytomegalovirus; CRE = Carbapenem-resistant Enterobacteriaceae; CRP = C-reactive protein; EBV = Epstein–Barr virus; ESBL = extended 1039 spectrum beta-lactamase; GGT = gamma-glutamyltransferase; GI = gastrointestinal; HAV = 1040 hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HEV = hepatitis E virus; 1041 1042 HIV = human immunodeficiency viruses; HTLV = human T-lymphotropic virus; IBD = 1043 inflammatory bowel disease; IBS = irritable bowel syndrome; MCV = mean corpuscular 1044 volume; MRSA = methicillin-resistant Staphylococcus aureus; NCEP = National Cholesterol 1045 Education Program; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; STEC 1046 = shigatoxigenic Escherichia coli; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; VRE = vancomycin-resistant Enterococci. 1047



Figure 1: A) Overview of the study. **B)** Glucose excursions during the oral glucose tolerance test. One person who was randomized to the FFT group had progressed to type 2 diabetes, which was not apparent at the time of screening. **C)** Total area under the curve (AUC) for glucose and **D)** for C-peptide did not significantly differ between the groups. Within both groups there was a small increase in glucose AUC between day 0 and 28, which was nominal significant within the FFT group, although this significance disappeared after correction for multiple testing. **E)** Insulin resistance (HOMA-IR) measures did not significantly differ between the groups, but significantly increased from day 0 to day 28 in both groups. **F)** Glucose variability, expressed as time between 3.9-10 mmol/L glucose, improved only within the FFT group between day 0 and day 28, which was nominal significant, but disappeared after correcting for multiple testing.



Figure 2: A) Overview of the faecal samples used for the bulk metagenomic sequencing (for bacteriome and phageome) and the metagenomic sequencing of the viral-like particles (VLP). **B)** The richness (number of observed species) in the bacteriome, phage virions (VLP) and bulk-derived phageome (WGS) from baseline until follow-up at day 28. Though there were no significant differences between the placebo and faecal filtrate group, the richness in the bacteriome reduced slightly after both interventions. A similar trend was observed in the phageome (mostly prophages present in bacterial hosts), while the richness in the VLP fraction tended to increase slightly at day 2 for both interventions. **C)** The alpha-diversity (Shannon index) of the bacteriome, phage virions (VLP) and bulk-derived phageome (WGS) from baseline until follow-up at day 28. Again, no significant differences were found between the interventions. Similar to the richness, the diversity of the bacteriome and phageome slightly decreased directly after the interventions. For the free phages, the diversity decreased slightly in the placebo group, but not in the faecal filtrate group.



Figure 3: A) The percentage of phages that were shared between the donor and recipient within the phageome and **B)** within the phage virions after the faecal filtrate transplantation. There was a slight, non-significant increase in the relative abundance of (pro)phages shared with the donor after the intervention, while the relative abundance of phage virions that were shared with the donor slightly decreased. **C)** The percentage of new phages that were present after the intervention within the bulk-derived phageome and **D**) within the phage virions. In both, the relative abundance of new phages increased over time and although not significant, this increase was slightly higher in the FFT group.



Figure 4: A) Principal response curve showing how the FFT group differs from the placebo (set to zero) in the bacteriome, bulk-derived phageome (WGS), and phage virion (VLP) composition. Significance in dispersion over time and at each separate time-point was calculated with permutation tests. **B)** Principal component analysis of VLP composition after centered log-ratio transformation. Large points show the mean of each group. **C)** Log fold change for all 216 viral populations (VP) indicated as differentially abundant by ANCOM-BC analysis. For legibility, VP names are not shown, these can be found in supplementary table S4. **D)** Bacterial host species of which the phages are enriched among differentially abundant VPs. The first column shows the number of differentially abundant VPs, the second the total number of VPs linked to a given host in the dataset, and stars show the level of significance after testing for enrichment with a hypergeometric test. **E)** splits up the data on the first column of D by participant group.



Figure 5: A) Correlations plots showing the change in relative abundance between day 0 and day 2 of viral populations (VP) versus host bacteria. Each datapoint represents the interactions between the VPs and metagenome assembled genomes (MAGs) of a particular species within a given sample. Linkages between VPs and MAGs were based on either CRISPR spacer hits or the presence of the VP as a prophage in the MAG. The Spearman correlation coefficient showed that phage-bacterium interactions in FFT samples tended toward antagonism, while those in placebo samples were protagonistic. **B)** Same as A, but showing the change in relative abundance between day 2 and day 28. The Spearman correlation coefficient showed that phage-bacterium interactions in placebo samples were protagonistic. **C)** Same as A and B, but showing the change in relative abundance between changes in abundance of VPs and host MAGs.

 Table 1: baseline characteristics of MetSyn subjects and lean donors.

		I	Metabolic	: Syndrom	ne subjects			Doi	nors	
	Plac (N=	e bo 12)	Fecal I (N=	Filtrate 12)	P-value	Com (N=	bined =24)	(N	=5)	p-value
Age (years)	49.3	(12.9)	54.8	(8.9)	0.20	52.0	(11.2)	32.0	(7.81)	0.003
Gender (n (%)) - Male - Female	7 5	(58.3%) (41.7%)	7 5	(58.3%) (41.7%)	>0.99	14 10	(58.3%) (41.7%)	3 2	(60.0%) (40.0%)	>0.99
#MetSyn Criteria (n (%)) - 1 - 2 - 3 - 4 - 5	- 4 5 3	(33.3%) (41.7%) (25.0%)	- - 7 4 1	(58.3%) (33.3%) (8.3%)	0.38	- - 11 9 4	(45.8%) (37.5%) (16.7%)	3 2 - -	(60.0%) (40.0%)	<0.001
BMI (kg/m²)	36.1	(4.2)	35.2	(5.7)	0.76	35.7	(4.9)	22.2	(1.9)	<0.001
WHR	0.98	(0.09)	1.00	(0.06)	0.49	0.99	(0.07)	0.83	(0.07)	<0.001
Systolic BP (mmHg)	147	(17)	131	(17)	0.047	139	(18)	124	(5)	0.039
Diastolic BP (mmHg)	93	(10)	90	(11)	0.74	91	(11)	76	(5)	0.004
Pulse (beats/min)	66	(12)	69	(11)	0.77	68	(11)	60	(11)	0.17
Glucose (mmol/L)	5.6	(0.5)	5.7	(0.5)	0.99	5.7	(0.5)	5.0	(0.4)	0.007
Insulin (nmol/L)	85	(24)	82	(28)	0.83	84	(26)	38	(12)	<0.001
HOMA-IR	2.91	(0.76)	2.92	(1.02)	>0.99	2.91	(0.88)	1.18	(0.37)	<0.001
HbA1c (mmol/mol)	36	(3.2)	36	(4.3)	0.75	36	(3.7)	34	(2.1)	0.19
Cholesterol (mmol/L)	5.30	(1.13)	5.76	(1.53)	0.63	5.53	(1.34)	4.01	(0.45)	0.015
HDL (mmol/L)	1.15	(0.22)	1.22	(0.23)	0.52	1.19	(0.22)	1.52	(0.26)	0.010
LDL (mmol/L)	3.43	(0.98)	3.71	(1.25)	0.89	3.57	(1.11)	2.09	(0.58)	0.003
Triglycerides (mmol/L)	1.60	(0.58)	1.84	(0.75)	0.59	1.72	(0.67)	0.89	(0.29)	0.007
CRP (mg/L)	4.0	(5.1)	6.2	(7.3)	0.25	5.1	(6.2)	1.4	(1.0)	0.07

Unless otherwise specified, data are reported as mean (SD). Statistical testing between the placebo and fecal filtrate groups and metabolic syndrome subjects and donors is performed by independent Mann-Whitney U test for continuous variables and by Chi-square test for categorical and binary variables. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.

Table 2: Differences in clinical safety markers after intervention

		PI (1	acebo N=12)	Feca (۱	I Filtrate √=12)	p-value
# AEs (n (%))	Total	13	(44.8%)	16	(55.2%)	
Relatedness of AEs (n (%))	Likely	0	(0%)	2	(12.5%)	0.21
	Possibly	2	(15.4%)	6	(37.5%)	
	Unlikely	4	(30.8%)	4	(25%)	
	Not	7	(53.9%)	4	(25%)	
# Subjects with AE (n (%))	≥1 AE	2	(16.7%)	6	(50%)	0.08
possibly or likely related	No AE	10	(83.3%)	6	(50%)	
Bilirubin (µmol/L)	Day 0	12	(6)	_* 15	(9)	0.39
	Day 28	9	(5)	12	(12)	
AF (U/L)	Day 0	76	(18)	69	(16)	0.17
	Day 28	79	(16)	68	(16)	
GGT (U/L)	Day 0	22	(10)	26	(11)	0.30
	Day 28	22	(12)	26	(9)	
ASAT (U/L)	Day 0	28	(8)	28	(7)	0.70
	Day 28	27	(8)	25	(7)	
ALAT (U/L)	Day 0	29	(11)	29	(10)	0.85
	Day 28	28	(10)	27	(9)	
Creatinine (µmol/L)	Day 0	85	(18)	76	(15)	0.20
	Day 28	82	(13)	75	(15)	
eGFR (ml/min/1.73m2)	Day 0	81	(12)	86	(6)	0.32
	Day 28	83	(9)	85	(7)	
Urea (mmol/L)	Day 0	4.3	(0.9)	4.4	(1.1)	* 0.65
	Day 28	4.8	(0.9)	5.1	(1.3)	
Haemoglobin (mmol/L)	Day 0	8.5	(1.0)	8.8	(0.8)	0.74
	Day 28	8.6	(0.9)	8.6	(0.6)	
Haematocrit (L/L)	Day 0	0.41	(0.04)	0.42	(0.03)	0.84
	Day 28	0.42	(0.04)	0.41	(0.03)	
MCV (fL)	Day 0	86.0	(4.7)	88.0	(2.7)	0.25
	Day 28	86.5	(4.5)	88.1	(3.0)	
Thrombocytes (x10^9/L)	Day 0	265	(87)	259	(45)	0.85
	Day 28	263	(73)	259	(48)	
Leukocytes (x10^9/L)	Day 0	6.2	(1.4)	6.2	(1.2)	0.56
	Day 28	5.8	(1.2)	6.3	(1.4)	
Eosinophils (x10^9/L)	Day 0	0.15	(0.07)	0.12	(0.06)	0.61
	Day 28	0.16	(0.08)	0.16	(0.11)	

It is r	It is made available under a CC-BY-NC-ND 4.0 International license .						
Basophils (x10^9/L)	Day 0	0.04 (0.01)	0.03 (0.02)	0.27			
	Day 28	0.04 (0.02)	0.04 (0.02)				
Neutrophils (x10^9/L)	Day 0	3.64 (1.14)	3.83 (0.97)	0.36			
	Day 28	3.25 (0.99)	3.82 (1.13)				
Lymphocytes (x10^9/L)	Day 0	1.83 (0.40)	1.70 (0.42)	0.61			
	Day 28	1.81 (0.29)	1.77 (0.48)				
Monocytes (x10^9/L)	Day 0	0.48 (0.11)	0.50 (0.10)	0.60			
	Day 28	0.47 (0.14)	0.50 (0.08)				
Immunoglobulins (x10^9/L)	Day 0	0.02 (0.01)	0.02 (0.01)	0.31			
	Day 28	0.02 (0.01)	0.02 (0.01)				

medRxiv preprint doi: https://doi.org/10.1101/2023.03.22.23287570; this version posted March 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Unless otherwise specified data are reported as mean (SD). Statistical testing for categorical and binary variables from the adverse events was done by Chi-square tests. Mixed model analyses were used to assess differences between groups and timepoints, whereafter post hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant differences between day 0 and 28 within a treatment group (* = P < 0.05). The p-value shows the overall effect of treatment on the variable and only when significant, the adjusted p-values from the post hoc tests are shown. EA = adverse event; AF = alkaline phosphatase; ALAT = alanine aminotransferase; ASAT = aspartate aminotransferase; eGFR = estimated glomerular filtration rate; GGT = gamma-glutamyltransferase; MCV = mean corpuscular volume.

		Pla (N	acebo N=12)	Feca (N	I Filtrato	e	p-value
BMI (kg/m²)	Day 0	35.8	(4.0)	35.3	(5.6)		0.75
	Day 28	36.1	(3.9)	35.3	(5.8)		
WHR	Day 0	0.97	(0.09)	0.99	(0.07)		0.58
	Day 28	0.97	(0.09)	0.99	(0.08)		
Systolic BP (mmHg)	Day 0	134	(15)	130	(17)		0.39
	Day 28	134	(16)	126	(17)		
Diastolic BP (mmHg)	Day 0	88	(11)	83	(14)		0.37
	Day 28	86	(9)	84	(14)		
Pulse (beats/min)	Day 0	66	(9)	70	(13)		0.33
	Day 28	65	(10)	70	(11)		
Glucose (mmol/L)	Day 0	5.5	(0.4)	5.8	(0.5)		0.19
	Day 28	5.7	(0.5)	5.9	(0.5)		
Insulin (nmol/L)	Day 0	71	(34)	* 72	(26)	**	0.76
	Day 28	87	(30)	93	(34)		
HOMA-IR	Day 0	2.41	(1.21)	2.57	(0.97)	**	0.55
	Day 28	3.05	(1.06)	3.41	(1.28)		
HbA1c (mmol/mol)	Day 0	36.8	(2.6)	35.4	(4.7)		0.53
	Day 28	35.5	(2.5)	35.0	(4.5)		
Cholesterol (mmol/L)	Day 0	4.87	(0.79)	5.38	(1.32)		0.28
	Day 28	4.92	(0.78)	5.33	(1.15)		
HDL (mmol/L)	Day 0	1.05	(0.20)	1.14	(0.18)		0.41
	Day 28	1.15	(0.30)	1.21	(0.17)		
LDL (mmol/L)	Day 0	3.06	(0.77)	3.43	(1.08)		0.32
	Day 28	3.03	(0.88)	3.42	(0.99)		
Triglycerides (mmol/L)	Day 0	1.68	(0.61)	1.80	(0.61)		0.96
	Day 28	1.66	(0.88)	1.56	(0.64)		
CRP (mg/L)	Day 0	3.0	(2.6)	5.1	(4.6)		0.17
	Day 28	2.9	(2.9)	4.6	(3.4)		

Table 3: Changes in physical and metabolic variables after intervention.

Unless otherwise specified, data are reported as mean (SD). Mixed model analyses were used to assess differences between groups and timepoints, whereafter post hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant differences between day 0 and 28 within a treatment group (* = p < 0.05; ** = p < 0.005). The p-value shows the overall effect of treatment on the variable and when significant, the adjusted p-values from the post hoc tests are shown. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.



Supplementary figure S1: A) Recruitment and screening of participants with the metabolic syndrome. **B)** Recruitment and screening of healthy donors for the sterile faecal filtrate. *BMI* = Body Mass Index; *D. fragilis* = Dientamoeba fragilis; ESBL = extended spectrum beta-lact-amase producer FMT = faecal microbiota transplantation; *H. pylori* = Helicobacter pylori; ICF = informed consent form; PPI = proton pump inhibitor; STEC = shigatoxigenic Escherichia coli.



Supplementary figure S2: A) Principal component analysis (PCA) of the viral populations (VP) within the phage virions (VLP) and **B)** bulk-derived phageome (WGS) between the subjects with metabolic syndrome in the faecal filtrate (FFT) and placebo groups and the healthy subjects who donated their stool at baseline. There were no differences in overall composition of the (pro)phages between the groups as determined by permutational analysis of variance (PERMANOVA). **C)** PCA of the VPs showing the difference in overall composition between the free phages (VLP) and bulk-derived phageome (WGS), which was statistically significant as determined by PERMANOVA (p = 0.001).



Supplementary figure S3: A) Production of the sterile faecal filtrate started the day before the administration to the MetSyn subjects. First, stool was collected from a healthy, thoroughly screened donor, which was homogenized with sterile saline. Large particles were then filtered from the faecal suspension using double sterile gauzes. Most bacteria were pelleted in two subsequent centrifugation steps, in which the suspension was spun for 1 hour at 10.000 RCF. The supernatant was then filtered through a sterile 0.2 μ m membrane using a tangential flow filtration device (Vivaflow® 50). The filtrate was stored overnight in a fridge until administration. **B)** The sterile faecal filtrate was administered to the patient via a nasoduodenal tube. The day prior to the administration, subjects were asked to clean their bowel using a laxative, which is a standard pre-treatment for FMT procedures in our hospital. Nasoduodenal tubes were placed with the help of a Cortrak device, making sure the nasoduodenal tube was correctly positioned. The faecal filtrate was slowly infused with a 60 ml syringe, on average 300 ml during a 15-20 min period. **C)** We confirmed with a qPCR for the bacterial 16S rRNA gene the absence of bacteria within the faecal filtrate, observing no colony-forming units in 100 ml of faecal filtrate (results not shown). **D)** Overview of the used pipeline for the microbiome shotgun sequencing and the VLP shotgun sequencing. *MAGs = Metagenome-assembled genomes; QC = quality control; VLP = viral-like particle; WGS = whole genome shotgun.*

Table S1: baseline dietary intake of participants.

	Placebo (N=12)	Fecal Filtrate (N=12)	P-value
Energy (kcal)	2199 (271)	2146 (580)	0.44
Fats (g)	93.4 (18.9)	93.3 (29.7)	>0.99
Saturated fats (g)	33.8 (9.5)	33.0 (11.8)	>0.99
Carbohydrates (g)	218.3 (51.8)	218.4 (70.3)	0.98
Sugars (g)	82.6 (30.4)	91.2 (44.5)	0.71
Proteins (g)	106.0 (26.4)	89.8 (25.0)	0.16
Fibers (g)	22.1 (6.7)	18.7 (6.0)	0.10
Salt (g)	7.72 (2.93)	7.50 (2.86)	0.89

Data are reported as mean (SD). Statistical testing between the placebo and fecal filtrate groups is performed by independent Mann-Whitney U test.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.22.23287570; this version posted March 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

		Placebo (N=12)	Fecal Filtrate (N=12)	P-value
Mean glucose (mmol/L)	Before	5.36 (0.41)	5.37 (0.70)	0.75
	After	5.34 (0.38)	5.33 (0.59)	
SD glucose (mmol/L)	Before	0.89 (0.19)	0.98 (0.42)	0.58
	After	0.94 (0.26)	0.94 (0.37)	
CV glucose (%)	Before	16.7 (3.6)	17.8 (5.1)	0.39
	After	17.5 (4.7)	17.3 (4.8)	
Min glucose (mmol/L)	Before	3.55 (0.47)	3.43 (0.37)	0.37
	After	3.51 (0.55)	3.46 (0.48)	
Max glucose (mmol/L)	Before	8.63 (1.21)	8.92 (1.74)	0.33
	After	9.18 (1.44)	8.82 (1.75)	
Time between 3.9-10 (%)	Before	97.1 (4.5)	95.5 (5.4)	0.19
	After	97.3 (4.4)	97.5 (3.3)	
Est. HbA1c (mmol/mol)	Before	31.0 (2.8)	31.1 (4.8)	0.76
	After	31.0 (2.6)	30.9 (4.1)	
AUC/day	Before	7621 (991)	7617 (823)	0.55
	After	7795 (671)	7841 (919)	
AUC>2SD/day	Before	33.0 (23.5)	32.3 (9.5)	0.53
	After	41.4 (15.5)	40.6 (13.9)	
CONGA 1 score	Before	0.99 (0.22)	1.09 (0.42)	0.28
	After	0.99 (0.25)	1.08 (0.46)	
MODD score	Before	0.82 (0.17)	0.87 (0.30)	0.41
	After	0.83 (0.20)	0.92 (0.39)	
MAGE score	Before	1.68 (0.87)	1.81 (1.03)	0.32
	After	1.45 (0.47)	1.53 (0.72)	

Table S2: Results from the continuous glucose monitoring devices measured one week before and one week after intervention.

Unless otherwise specified data are reported as mean (SD). Mixed model analyses were used to assess differences between groups and timepoints, whereafter post hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant differences between the week before and after intervention within a treatment group (* = P<0.05). The P-value shows the overall effect of treatment on the variable and only when significant, the adjusted P-values from the post hoc tests are shown. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.

VP	pval	qval	logFoldChange	se	group
k141_101636	0	0	-1,312270403	0	FFT
k141_102263	0	0	-3,425670312	0	FFT
k141_106332	0	0	2,141087406	0	Placebo
k141_10756	3,15E- 05	0,01761 7	5,563830378	1,33667 8	Placebo
k141_10974	0	0	2,992127571	0	Placebo
k141_109788	0	0	-1,375429495	0	FFT
k141_11046	0	0	-0,962092831	0	FFT
k141_111221	0	0	-1,453290059	0	FFT
k141_112035	0	0	-3,3466534	0	FFT
k141_112086	0	0	3,104251722	0	Placebo
k141_112454	0	0	2,827791675	0	Placebo
k141_114032	0	0	3,294213547	0	Placebo
k141_115416	0	0	-3,333017439	0	FFT
k141_11637	0	0	-1,401340226	0	FFT
k141_116603	0	0	-1,086477395	0	FFT
k141_11730	0	0	2,503402317	0	Placebo
k141_117761	0	0	2,60659704	0	Placebo
k141_119045	0	0	3,564093484	0	Placebo
k141_125759	0	0	2,952167989	0	Placebo
k141_125789	0	0	-2,067780338	0	FFT
k141_127001	0	0	2,749757395	0	Placebo
k141_127793	0	0	3,893689588	0	Placebo
k141_128877	0	0	2,126697451	0	Placebo
k141_129314	0	0	-3,025927151	0	FFT
k141_134605	0	0	-3,292277297	0	FFT
k141_136941	0	0	-1,277341305	0	FFT
k141_144884	0	0	-1,056548645	0	FFT
k141_148750	0	0	-2,604840048	0	FFT

Table S3: Differentially a	abundant viral populat	ions within the VLP	phageome on	day 2.
------------------------------------	------------------------	---------------------	-------------	--------

VP	pval	qval	logFoldChange	se	group
k141_151057	0	0	-2,126112954	0	FFT
k141_15115	0	0	-1,817210155	0	FFT
k141_151150_1	0	0	-1,438756269	0	FFT
k141_155147	0	0	-2,05749536	0	FFT
k141_155148	0	0	-2,000236329	0	FFT
k141_157965	0	0	3,605717171	0	Placebo
k141_158364_dd0	0	0	2,187755549	0	Placebo
k141_159779	0	0	2,239116789	0	Placebo
k141_159817	0	0	2,120457402	0	Placebo
k141_161268	0	0	2,586662105	0	Placebo
k141_16485	0	0	-0,9932292	0	FFT
k141_168380	0	0	-0,855276508	0	FFT
k141_170194	0	0	-1,719024655	0	FFT
k141_172768	0	0	2,601083591	0	Placebo
k141_177455	0	0	-1,6607376	0	FFT
k141_178132	0	0	-3,741877558	0	FFT
k141_179489	0	0	-1,950095228	0	FFT
k141_180382	0	0	-2,089345501	0	FFT
k141_180582	0	0	-2,640651363	0	FFT
k141_183972	0	0	1,804298089	0	Placebo
k141_187104	0	0	-2,543229341	0	FFT
k141_190599	0	0	2,052310446	0	Placebo
k141_193501	0	0	-1,592000751	0	FFT
k141_194688	0	0	-2,76451363	0	FFT
k141_198836	0	0	2,803009107	0	Placebo
k141_199825	0	0	2,928490685	0	Placebo
k141_200995	0	0	-3,144102303	0	FFT
k141_202610	0	0	-1,770629428	0	FFT
k141_203084	0	0	-2,053202875	0	FFT
k141_203139	0	0	-1,891220481	0	FFT

VP	pval	qval	logFoldChange	se	group
k141_206365	0	0	-1,129053941	0	FFT
k141_20647	0	0	2,789096554	0	Placebo
k141_206857	0	0	-2,412442161	0	FFT
k141_206980	0	0	-3,31697338	0	FFT
k141_209161	0	0	-1,438294024	0	FFT
k141_210395	0	0	-0,724058392	0	FFT
k141_212095	0	0	-2,712640916	0	FFT
k141_21677	0	0	-2,358183947	0	FFT
k141_21921	0	0	2,540045123	0	Placebo
k141_22024_dd0	0	0	2,51659235	0	Placebo
k141_22092	0	0	2,069173303	0	Placebo
k141_22286	0	0	-2,327372111	0	FFT
k141_233879	0	0	-3,125257489	0	FFT
k141_234523	0	0	-1,801032357	0	FFT
k141_24053	0	0	-2,524172434	0	FFT
k141_242230	0	0	-2,326845426	0	FFT
k141_251286	0	0	-2,990744268	0	FFT
k141_254742	0	0	-3,43670237	0	FFT
k141_26090	0	0	-1,358243264	0	FFT
k141_261577	0	0	-3,163270958	0	FFT
k141_261638	0	0	-1,647922065	0	FFT
k141_26711	0	0	-3,241422347	0	FFT
k141_29930	0	0	-2,376517194	0	FFT
k141_31428	0	0	1,973812533	0	Placebo
k141_31803	0	0	-1,671578554	0	FFT
k141_33432	0	0	-2,056664518	0	FFT
k141_35243	0	0	-3,760521856	0	FFT
k141_35795_dd0	0	0	3,691541787	0	Placebo
k141_3625_dd0	0	0	-1,698719279	0	FFT
k141_37010	0	0	-1,069830093	0	FFT

VP	pval	qval	logFoldChange	se	group
k141_39074	0	0	-1,222252937	0	FFT
k141_3911	0	0	-2,633100111	0	FFT
k141_4122_dd0	0	0	-2,987212781	0	FFT
k141_41301	0	0	-1,885353218	0	FFT
k141_4169	0	0	-2,393193791	0	FFT
k141_4369	0	0	-1,935620837	0	FFT
k141_44711	0	0	-3,161460603	0	FFT
k141_44931	0	0	-2,0575856	0	FFT
k141_46528	0	0	-1,495563103	0	FFT
k141_46916	0	0	2,093268463	0	Placebo
k141_50348	0	0	3,107055989	0	Placebo
k141_5205	0	0	2,72654519	0	Placebo
k141_53075	0	0	-1,489601858	0	FFT
k141_55453	0	0	-3,434321805	0	FFT
k141_55621	0	0	-1,300409181	0	FFT
k141_56634	0	0	4,455598366	0	Placebo
k141_59760	0	0	1,789431267	0	Placebo
k141_60050	0	0	-0,956952804	0	FFT
k141_61833	0	0	-1,567715024	0	FFT
k141_63935	0	0	-1,327620271	0	FFT
k141_67734	0	0	-4,292240944	0	FFT
k141_69194	0	0	-2,556814394	0	FFT
k141_74094	0	0	3,109323778	0	Placebo
k141_74505	3,96E- 05	0,01761 7	-7,711976292	1,87653 3	FFT
k141_79107	0	0	2,828070797	0	Placebo
k141_80279	0	0	-2,065397124	0	FFT
k141_81009	0	0	-1,448638782	0	FFT
k141_82007	0	0	-3,740279483	0	FFT
k141_82108	0	0	-1,809720032	0	FFT

VP	pval	qval	logFoldChange	se	group
k141_82112	0	0	4,004910143	0	Placebo
k141_82230	0	0	-1,579494971	0	FFT
k141_82338	0	0	4,826652241	0	Placebo
k141_83004	0	0	-3,415628397	0	FFT
k141_83924_1	0	0	-2,644498789	0	FFT
k141_85097	0	0	2,446543432	0	Placebo
k141_86169	0	0	-2,183651358	0	FFT
k141_86881	0	0	-2,862591441	0	FFT
k141_88495	0	0	-1,906655653	0	FFT
k141_90585	0	0	-2,187977143	0	FFT
k141_91439	0	0	-2,668648043	0	FFT
k141_9187	0	0	-1,848616845	0	FFT
k141_92904	0	0	-2,144436067	0	FFT
k141_9625	0	0	-1,452380852	0	FFT
k141_96613	2,51E- 05	0,01761 7	6,630253453	1,57339 8	Placebo
NODE_1050_length_55972_cov_117.387789	0	0	2,531114889	0	Placebo
NODE_1088_length_50062_cov_24.574080	0	0	-2,93117887	0	FFT
NODE_11335_length_8998_cov_10.494689_ 1	0	0	-0,601774626	0	FFT
NODE_1134_length_59393_cov_104.580977	0	0	2,37934413	0	Placebo
NODE_117_length_159210_cov_262.254262	0	0	2,031024034	0	Placebo
NODE_11810_length_12626_cov_114.89404 2	0	0	2,069339833	0	Placebo
NODE_12_length_255453_cov_103.251267	0	0	-1,747789933	0	FFT
NODE_126_length_166884_cov_17.994923_ 1	0	0	2,08420609	0	Placebo
NODE_1295_length_46075_cov_193.830769	0	0	-1,843780627	0	FFT
NODE_1308_length_46212_cov_78.801937	0	0	-0,776757044	0	FFT
NODE_14389_length_7854_cov_4.950635	0	0	-0,872967795	0	FFT
NODE_1521_length_45571_cov_101.768455 _1	0	0	-1,22638905	0	FFT

VP	pval	qval	logFoldChange	se	group
NODE_16_length_348042_cov_111.631501	0	0	-2,419872421	0	FFT
NODE_1611_length_46733_cov_17.599276_ 1	0	0	-0,959774804	0	FFT
NODE_16481_length_6520_cov_3.993039	0	0	1,838474041	0	Placebo
NODE_1723_length_41816_cov_164.001125	0	0	2,358019402	0	Placebo
NODE_173_length_134896_cov_7.537018	0	0	-1,286404349	0	FFT
NODE_181_length_130009_cov_37.555966	0	0	3,181861878	0	Placebo
NODE_1820_length_49117_cov_63.722739	0	0	-1,471679648	0	FFT
NODE_1855_length_40494_cov_32.093326	0	0	-1,429529654	0	FFT
NODE_19219_length_6100_cov_6.030108	0	0	-1,02553031	0	FFT
NODE_1966_length_28637_cov_22.336540	0	0	2,031166381	0	Placebo
NODE_19722_length_5869_cov_356.798934 _1	0	0	-0,984707094	0	FFT
NODE_2038_length_45256_cov_74.924847	0	0	-1,515460846	0	FFT
NODE_2060_length_37621_cov_353.873929	0	0	3,213898211	0	Placebo
NODE_20787_length_5324_cov_191.477130	0	0	-1,061439074	0	FFT
NODE_21872_length_5396_cov_6.531361	0	0	-0,764365111	0	FFT
NODE_22_length_277594_cov_157.660469	0	0	2,416492446	0	Placebo
NODE_2266_length_36032_cov_331.272146	0	0	2,230878198	0	Placebo
NODE_2327_length_41251_cov_43.961088	0	0	-2,969473485	0	FFT
NODE_248_length_103337_cov_52.835799	0	0	-1,493380762	0	FFT
NODE_256_length_119475_cov_53.713440	0	0	-1,51687262	0	FFT
NODE_2719_length_30411_cov_12.217321	0	0	-1,271940551	0	FFT
NODE_2721_length_29602_cov_28.053948	0	0	-1,238190863	0	FFT
NODE_274_length_129349_cov_49.597383	0	0	-1,784760686	0	FFT
NODE_280_length_83712_cov_192.013531_ 1	0	0	-0,970377102	0	FFT
NODE_303_length_102870_cov_97.940048	0	0	-1,341981246	0	FFT
NODE_311_length_101570_cov_39.049008	0	0	-1,467845887	0	FFT
NODE_3347_length_27440_cov_41.328611	0	0	2,852704375	0	Placebo
NODE_3362_length_31037_cov_71.806791	0	0	-1,727094403	0	FFT

VP	pval	qval	logFoldChange	se	group
NODE_3432_length_26142_cov_7.044045	0	0	-1,472020258	0	FFT
NODE_3515_length_22106_cov_30.525056	0	0	-1,364903091	0	FFT
NODE_3517_length_22201_cov_1016.88426 8	0	0	2,107768855	0	Placebo
NODE_352_length_98964_cov_58.192854	0	0	-1,14321944	0	FFT
NODE_3646_length_21525_cov_5.247322	0	0	-0,984906952	0	FFT
NODE_3879_length_25805_cov_66.517631	0	0	2,214577766	0	Placebo
NODE_429_length_105199_cov_116.740565	0	0	-2,314109721	0	FFT
NODE_4406_length_18765_cov_17.720898	0	0	2,703695862	0	Placebo
NODE_448_length_82328_cov_242.488848	0	0	-1,662422888	0	FFT
NODE_4564_length_24187_cov_17.473852	0	0	-0,722987639	0	FFT
NODE_4601_length_26378_cov_20.827565	0	0	-1,502111658	0	FFT
NODE_4627_length_18353_cov_21.879167	0	0	-1,286468209	0	FFT
NODE_467_length_77994_cov_91.581044	0	0	-3,186160602	0	FFT
NODE_47_length_245394_cov_57.668312	0	0	-2,640133738	0	FFT
NODE_4813_length_20685_cov_8.087009	0	0	-1,581883112	0	FFT
NODE_484_length_65443_cov_20.397810	0	0	-1,471379026	0	FFT
NODE_50_length_209392_cov_41.016590	0	0	-1,90625978	0	FFT
NODE_50_length_233022_cov_28.249211_1	0	0	-1,529824626	0	FFT
NODE_508_length_81568_cov_59.029860	0	0	-1,914695115	0	FFT
NODE_5219_length_19530_cov_658.240770	0	0	2,633221576	0	Placebo
NODE_54_length_230968_cov_83.819361	0	0	-2,814716438	0	FFT
NODE_553_length_96146_cov_103.323038	0	0	-1,664989219	0	FFT
NODE_557_length_72009_cov_41.425842	0	0	2,774501699	0	Placebo
NODE_5611_length_15188_cov_13.744069	0	0	-1,115581586	0	FFT
NODE_5616_length_15178_cov_8.516234	0	0	-1,895818223	0	FFT
NODE_564_length_77280_cov_7.587258	0	0	2,502440408	0	Placebo
NODE_60_length_202357_cov_80.827332	0	0	2,377545927	0	Placebo
NODE_607_length_71456_cov_27.699164	0	0	-1,449995967	0	FFT
NODE_617_length_77023_cov_22.896113	0	0	-2,524199258	0	FFT

medRxiv preprint doi: https://doi.org/10.1101/2023.03.22.23287570; this version posted March 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-	IC-ND 4.0 International license .
-------------------------------------	-----------------------------------

VP	pval	qval	logFoldChange	se	group
NODE_6423_length_14205_cov_50.890742	0	0	2,068337809	0	Placebo
NODE_69_length_193138_cov_81.982287_1	0	0	-0,910501471	0	FFT
NODE_703_length_67960_cov_56.511420	0	0	-2,240779078	0	FFT
NODE_707_length_80900_cov_37.907774_1	0	0	2,650128324	0	Placebo
NODE_750_length_74789_cov_31.001913	0	0	3,218506179	0	Placebo
NODE_7814_length_12923_cov_5.996114	0	0	-1,126018207	0	FFT
NODE_795_length_63964_cov_11.828146	0	0	-1,795548672	0	FFT
NODE_814_length_67071_cov_27.754984	0	0	-2,214361803	0	FFT
NODE_8630_length_10350_cov_19.728120	0	0	2,893361393	0	Placebo
NODE_864_length_75884_cov_56.634441	0	0	-1,630389453	0	FFT
NODE_869_length_61737_cov_16.350880	0	0	3,034395765	0	Placebo
NODE_871_length_69794_cov_33.084601	0	0	-1,352282376	0	FFT
NODE_904_length_60482_cov_105.096497	0	0	-1,470887833	0	FFT
NODE_944_length_45651_cov_224.138302	0	0	-1,210253855	0	FFT
NODE_9981_length_7650_cov_12.550757_1	0	0	-1,017230505	0	FFT

medRxiv preprint doi: https://doi.org/10.1101/2023.03.22.23287570; this version posted March 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table S4: In- and exclusion criteria for study participants.

INCLUSION CRITERIA

- Caucasian male or female
- Age: 18 65 years old
- BMI ≥ 25 kg/m²
- At least 3 of the following criteria:
 - o Fasting plasma glucose ≥ 5.6 mmol/L, or HOMA-IR index ≥2.5 (HOMA-IR is measured as (fasting insulin (pmol/L) x fasting glucose (mmol/L)) / 135)
 - o Waist-circumference ≥ 102 cm for males, ≥ 89 cm for females
 - HDL-cholesterol ≤ 1.02 mmol/L for males, ≤ 1.29 mmol/L for females
 - Blood pressure ≥ 130/85 mmHg
 - Triglycerides \geq 1.7 mmol/L
- Subjects should be able to give informed consent

EXCLUSION CRITERIA

- A history of cardiovascular event (e.g., CVA or MI) or pacemaker implantation
- Use of any medication including proton pump inhibitors, antibiotics, and pro-/prebiotics in the past three months or during the study period
- (Expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count < 240/mm3)
- Presence of overt T1DM or T2D
- History of chronic diarrhoea (≥3 stools/day for >4 weeks), chronic obstipation (<2 defecations/week for >3 months), IBS (according to Rome IV criteria), or IBD.
- Smoking or illicit drug use in the past three months or use during the study period
- Alcohol abuse (>5 units/day on average) in the past three months or use of > 2 units/day of alcohol during the study period
- History of cholecystectomy

Abbreviations: CVA = cerebrovascular accident; HDL = high-density lipoprotein; HIV = human immunodeficiency viruses; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; MI = myocardial infarction; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

Table S5: In- and exclusion criteria for faeces donors.

INCLUSION CRITERIA

- Caucasian male or female
- Age: 18 65 years old
- BMI: 18-25 kg/m²
- Subjects should be able to give informed consent

EXCLUSION CRITERIA

Positive test for infectious agent

- Positive Dual Faeces Test for Giardia Lamblia, Dientamoeba fragilis, Entamoeba histolytica, Microsporidium spp., Cryptosporidium spp., Cyclospora, Isospora, or Blastocystis Hominis. Positive microscopic exam for eggs, cysts, and larvae (e.g. helminth eggs)
- Presence of faecal bacterial pathogens Salmonella spp., Shigella spp., Campylobacter spp., Yersinia spp., C. difficile, H. pylori, STEC, Aeromonas spp., or Pleisiomonas shigelloides in faeces
- Presence of ESBL producers, CRE, VRE, or MRSA in faeces
- Presence of Rotavirus, Norovirus I/II, Enterovirus, Parechovirus, Astrovirus, Sapovirus, or Adenovirus in faeces
- Presence of SARS-CoV-2 in faeces
- Positive serologic test for HIV 1/2, HAV, HBV, HCV, HEV, active CMV or EBV, Strongyloides, or Treponema pallidum

Risk of infectious agent

- History of, or known exposure to HIV, HBV, HCV, syphilis, HTLV I and II, malaria, trypanosomiasis, or tuberculosis
- Known systemic infection not controlled at the time of donation
- Unsafe sex practice
- Previous reception of tissue/organ transplant
- Previous (<12 months) reception of blood products
- Recent (<6 months) needle stick accident
- Recent (<6 months) body tattoo, piercing, earring, or acupuncture
- Recent medical treatment in poorly hygienic conditions
- Risk of transmission of diseases caused by prions
- Recent parasitosis or infection from rotavirus, Giardia lamblia, and other microbes with GI involvement
- Recent travel to tropical countries, countries at high risk of communicable diseases, or traveller's diarrhoea
- Recent (<6 months) history of vaccination with a live attenuated virus, if there is a possible risk of transmission
- Healthcare providers having frequent patient contact
- Individual working with animals

medRxiv preprint doi: https://doi.org/10.1101/2023.03.22.23287570; this version posted March 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Gastrointestinal comorbidities

- History of IBS (according to Rome IV criteria), IBD, functional chronic constipation, or other chronic GI disorders
- History of chronic, systemic autoimmune disorders with GI involvement, such as coeliac disease
- History of, or high risk for, GI cancer, or polyposis
- Recent appearance of diarrhoea (≥3 stools/day), and/or haematochezia
- Elevated faecal calprotectin (> 50 µg/g)

Factors affecting intestinal microbiota composition

- Use of any medication including proton pump inhibitors, antibiotics, and pro-/prebiotics in the past three months or during the study period
- Smoking or illicit drug use in the past three months or during the study period
- History of cholecystectomy

Other conditions

- History of neurological or neurodegenerative disorders
- History of psychiatric conditions
- Presence of chronic low-grade inflammation or metabolic syndrome (NCEP criteria)
- Presence of T1DM, T2DM, or hypertension
- Alcohol abuse (>5 units/day on average) in the past three months or use of > 2 units/day of alcohol during the study period
- Abnormal liver or renal function (creatinine >110 μmol/l, ureum >8,2 mmol/l, ASAT > 40 U/L, ALAT > 45 U/L, AF > 120 U/L, GGT > 60 U/L, bilirubin >17μmol/L), or impaired immunity (CRP > 5 mg/L, haemoglobin < 8,5 mmol/L, MCV: 80-100 fL, leukocytes: 4,0-10,5 x109/L, thrombocytes: 150-400 x10⁹/L).

Abbreviations: AF = alkaline phosphatase; ALAT = alanine aminotransferase; ASAT = aspartateaminotransferase; CMV = cytomegalovirus; CRE = Carbapenem-resistant Enterobacteriaceae;CRP = C-reactive protein; EBV = Epstein–Barr virus; ESBL = extended spectrum betalactamase; GGT = gamma-glutamyltransferase; GI = gastrointestinal; HAV = hepatitis A virus;HBV = hepatitis B virus; HCV = hepatitis C virus; HEV = hepatitis E virus; HIV = humanimmunodeficiency viruses; HTLV = human T-lymphotropic virus; IBD = inflammatory boweldisease; IBS = irritable bowel syndrome; MCV = mean corpuscular volume; MRSA = methicillinresistant Staphylococcus aureus; NCEP = National Cholesterol Education Program; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; STEC = shigatoxigenic Escherichiacoli; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; VRE = vancomycinresistant Enterococci.